



EFSA ; Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1): Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th meeting)

EFSA Publication

Link to article, DOI:
[10.2903/j.efsa.2011.2314](https://doi.org/10.2903/j.efsa.2011.2314)

Publication date:
2011

Document Version
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

Citation (APA):
EFSA Publication (2011). *EFSA ; Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1): Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th meeting)*. European Food Safety Authority. EFSA Journal No. 2314 <https://doi.org/10.2903/j.efsa.2011.2314>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

SCIENTIFIC OPINION

Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1):

Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th meeting)¹

EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF)^{2, 3}

European Food Safety Authority (EFSA), Parma, Italy

ABSTRACT

The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety Authority was requested to evaluate 14 flavouring substances in the Revision 1 of Flavouring Group Evaluation 66, using the Procedure in Commission Regulation (EC) No 1565/2000. None of the substances were considered to have genotoxic potential. The substances were evaluated through a stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake from current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The Panel concluded that the 14 substances [FL-no: 13.001, 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] do not give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI approach.

© European Food Safety Authority, 2011

1 On request from the Commission, Question No EFSA-Q-2011-00863, EFSA-Q-2011-00864, EFSA-Q-2011-00865, EFSA-Q-2011-00866 adopted on 6 July 2011.

2 Panel members: Arturo Anadon, Mona-Lise Binderup, Wilfried Bursch, Laurence Castle, Riccardo Crebelli, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Thomas Haertle, Trine Husøy, Klaus-Dieter Jany, Catherine Leclercq, Jean Claude Lhuguenot, Wim Mennes, Maria Rosaria Milana, Karla Pfaff, Kettil Svensson, Fidel Toldra, Rosemary Waring, Detlef Wölflle. Correspondence: cef-unit@efsa.europa.eu

3 Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings for the preparation of this Opinion: Ulla Beckman Sundh, Vibe Beltoft, Wilfried Bursch, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Frances Hill, Trine Husøy, John Christian Larsen, Pia Lund, Wim Mennes, Gerard Mulder, Karin Nørby, Iona Pratt, Gerrit Speijers, Harriet Wallin and EFSA's staff member Kim Rygaard Nielsen for the preparatory work on this scientific Opinion.

Suggested citation: EFSA ; Scientific Opinion on Flavouring Group Evaluation 66, Revision 1 (FGE.66Rev1): Consideration of Furfuryl Alcohol and Related Flavouring Substances Evaluated by JECFA (55th meeting). EFSA Journal 2011; 9(9):2314. [44 pp.]. doi:10.2903/j.efsa.2011.2314. Available online: www.efsa.europa.eu/efsajournal.htm

SUMMARY

The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the implications for human health of chemically defined flavouring substances used in or on foodstuffs in the Member States. In particular, the Panel was requested to consider the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, which was adopted by Commission Decision 1999/217/EC and its consecutive amendments.

The JECFA has evaluated 15 furfuryl alcohol derivatives at their 55th meeting. The Panel concluded that 14 substances in Flavouring Group Evaluation 66 (FGE.66) are structurally related to the subgroup of 10 furfuryl derivatives in the group of furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms evaluated by EFSA in FGE.13, Revision 2 (FGE.13Rev2). The 15th substance, 2-Benzofurancarboxaldehyde [FL-no: 13.031], is considered too structurally different from the other 14 to be included in the present FGE. This substance will be evaluated in FGE.67Rev1.

Eight of the candidate substances in this FGE are alpha,beta-unsaturated aldehydes or precursors for such which is a structural alert for genotoxicity. These eight substances [FL-no: 13.001, 13.018, 13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] have initially been considered with respect to genotoxicity. The Panel concluded that for all eight substances the genotoxicity data available do not preclude their evaluation through the Procedure. No concern for genotoxicity was identified for the remaining six substances without the alpha,beta structural alert [FL-no: 13.002, 13.003, 13.005, 13.025, 13.038 and 13.073].

The Panel agrees with the application of the Procedure as performed by the JECFA for 13 substances considered in this FGE [FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128]. In contrast to the JECFA, the Panel evaluated the fourteenth substance [FL-no: 13.001] by comparison with a Benchmark Dose, Lower Confidence Limit (BMDL) for a metabolite (5-hydroxymethylfurfural; [FL-no: 13.139]). For none of the candidate substances in this FGE a safety concern was identified.

For one substance, furfural [FL-no: 13.018], use levels have been provided by Industry and an mTAMDI figure of 9700 microgram/person/day could be calculated. For the remaining 13 substances [FL-no: 13.001, 13.002, 13.003, 13.005, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] use levels are needed to calculate the mTAMDI in order to identify those flavouring substances that need more refined exposure assessment and to finalise the evaluation.

Adequate specifications including purity criteria and identity test are available for all 14 JECFA evaluated substances considered in the present FGE.

Thus, for all 14 JECFA evaluated furfuryl derivatives [FL-no: 13.001, 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] the Panel agrees with the JECFA conclusion "No safety concern at estimated levels of intake as flavouring substances" based on the MSDI approach.

KEY WORDS

Alpha,beta-unsaturated aldehydes, furfural, furfuryl derivatives, furfuryl alcohol, flavouring substances, safety evaluation, FGE.66, FGE.66Rev1.

TABLE OF CONTENTS

| | |
|--|----|
| Abstract | 1 |
| Summary | 2 |
| Table of contents | 3 |
| Background | 4 |
| Terms of reference | 4 |
| Assessment | 4 |
| History of the Evaluation of the Substances in the present FGE | 6 |
| 1. Presentation of the Substances in the JECFA Flavouring Group | 7 |
| 1.1. Description | 7 |
| 1.1.1. JECFA Status | 7 |
| 1.1.2. EFSA Considerations | 7 |
| 1.2. Isomers | 7 |
| 1.2.1. Status | 7 |
| 1.3. Specifications | 7 |
| 1.3.1. Status | 7 |
| 1.3.2. EFSA Considerations | 8 |
| 2. Intake Estimations | 8 |
| 2.1. Status | 8 |
| 2.2. EFSA Considerations | 8 |
| 3. Genotoxicity Data | 8 |
| 3.1. Genotoxicity Studies – Text taken from the JECFA (JECFA, 2001b) | 8 |
| 3.2. Genotoxicity on furfural – Text taken from the JECFA (JECFA, 2001b) | 9 |
| 3.3. Genotoxicity Studies – Text taken from FGE.13Rev2 (EFSA, 2011h) | 9 |
| 3.4. SCF Opinion on Furfural and Furfural Diethylacetal (SCF, 2003a) | 13 |
| 3.5. EFSA Opinion on Furfural and Furfural Diethylacetal (EFSA, 2004c) | 14 |
| 3.6. EFSA Considerations | 16 |
| 4. Application of the Procedure | 16 |
| 4.1. Application of the Procedure to Furfuryl Alcohol and Related Substances, Text taken from the JECFA (JECFA, 2001b) | 16 |
| 4.2. Application of the Procedure to a Group of Furfuryl and Furan Derivatives with and without Additional Side-Chain Substituents and Heteroatoms Evaluated by EFSA, Text taken from FGE.13Rev2 (EFSA, 2011h) | 17 |
| 4.3. EFSA Considerations | 18 |
| 5. Conclusion | 19 |
| Table 1: Specification Summary | 20 |
| Table 2: Genotoxicity Data | 22 |
| Table 2.3: Genotoxicity (<i>in vivo</i>) evaluated by EFSA in FGE.13Rev2 (EFSA, 2011h) | 30 |
| Table 3: Summary of Safety Evaluations | 34 |
| References | 37 |
| Abbreviations | 43 |

BACKGROUND

Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a Procedure for the establishment of a list of flavouring substances, the use of which will be authorised to the exclusion of all other substances in the EU. In application of that Regulation, a Register of flavouring substances used in or on foodstuffs in the Member States was adopted by Commission Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are divided into 34 chemical groups. Substances within a group should have some metabolic and biological behaviour in common.

Substances which are listed in the Register are to be evaluated according to the evaluation programme laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the Opinion of the Scientific Committee on Food (SCF, 1999a).

Commission Regulation (EC) No 1565/2000 lays down that substances that are contained in the Register and will be classified in the future by the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) so as to present no safety concern at current levels of intake will be considered by the European Food Safety Authority (EFSA), who may then decide that no further evaluation is necessary.

In the period 2000 - 2008, during its 55th, 57th, 59th, 61st, 63rd, 65th, 68th and 69th meetings, the JECFA evaluated about 1000 substances, which are in the EU Register.

TERMS OF REFERENCE

EFSA is requested to consider the JECFA evaluations of flavouring substances assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a). These flavouring substances are listed in the Register which was adopted by Commission Decision 1999/217 EC (EC, 1999a) and its consecutive amendments.

After the finalisation of the evaluation programme 31 December 2009, in their letter of the 11 September 2009, the Commission requested EFSA to carry out a re-evaluation of 5-methylfurfural [FL-no: 13.001] in accordance with Commission Regulation (EC) No 1565/2000 (EC, 2000a).

ASSESSMENT

The approach used by EFSA for safety evaluation of flavouring substances is referred to in Commission Regulation (EC) No 1565/2000 (EC, 2000a), hereafter named the “EFSA Procedure”. This Procedure is based on the Opinion of the Scientific Committee on Food (SCF, 1999a), which has been derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food Additives (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b), hereafter named the “JECFA Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the Panel) compares the JECFA evaluation of structurally related substances with the result of a corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring substances are of no safety concern at their estimated levels of intake, whether additional data are required or whether certain substances should not be put through the EFSA Procedure.

The following issues are of special importance.

Intake

In its evaluation, the Panel as a default uses the “Maximised Survey-derived Daily Intake” (MSDI) approach to estimate the *per capita* intakes of the flavouring substances in Europe.

In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both European and USA production figures. The highest of the two MSDI figures is used in the evaluation by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of these figures. For Register substances for which this is the case the Panel will need EU production figures in order to finalise the evaluation.

When the Panel examined the information provided by the European Flavour Industry on the use levels in various foods, it appeared obvious that the MSDI approach in a number of cases would grossly underestimate the intake by regular consumers of products flavoured at the use level reported by the Industry, especially in those cases where the annual production values were reported to be small. In consequence, the Panel had reservations about the data on use and use levels provided and the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting considered “how to improve the identification and assessment of flavouring agents, for which the MSDI estimates may be substantially lower than the dietary exposures that would be estimated from the anticipated average use levels in foods” (JECFA, 2006c).

In the absence of more accurate information that would enable the Panel to make a more realistic estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” (mTAMDI) approach based on the normal use levels reported by Industry.

As information on use levels for the flavouring substances has not been requested by the JECFA or if it has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on use levels in order to finalise the evaluation.

Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA

The JECFA uses the threshold of concern of 1.5 microgram/person/day as part of the evaluation procedure:

“The Committee noted that this value was based on a risk analysis of known carcinogens which involved several conservative assumptions. The use of this value was supported by additional information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the Committee, flavouring substances for which insufficient data are available for them to be evaluated using earlier steps in the Procedure, but for which the intake would not exceed 1.5 microgram per person per day would not be expected to present a safety concern. The Committee recommended that the Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended to include the last step on the right-hand side of the original procedure (“Do the condition of use result in an intake greater than 1.5 microgram per day?”) (JECFA, 1999b).

In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does not make use of this threshold of 1.5 microgram per person per day.

Genotoxicity

As reflected in the Opinion of SCF (SCF, 1999a), the Panel has in its evaluation focussed on a possible genotoxic potential of the flavouring substances or of structurally related substances. Generally, substances for which the Panel has concluded that there is an indication of genotoxic potential *in vitro*, will not be evaluated using the EFSA Procedure until further genotoxicity data are

provided. Substances for which a genotoxic potential *in vivo* has been concluded, will not be evaluated through the Procedure.

Specifications

Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of the JECFA, since the Panel requests information on e.g. isomerism.

Structural Relationship

In the consideration of the JECFA evaluated substances, the Panel will examine the structural relationship and metabolism features of the substances within the flavouring group and compare this with the corresponding FGE.

HISTORY OF THE EVALUATION OF THE SUBSTANCES IN THE PRESENT FGE

The Flavouring Group Evaluation 66 concerned furfuryl alcohol and 13 related substances evaluated by the JECFA at their 55th meeting. Eight of the 14 substances are alpha,beta-unsaturated aldehydes or precursors for such, which the Panel considers to be a structural alert for genotoxicity. Accordingly, these eight substances were initially considered with respect to genotoxicity (see Section 1.1.2). The Panel concluded in FGE.218 (EFSA, 2009s) that the alpha,beta-unsaturated structure did not give rise to concern for genotoxicity in these eight substances, but for one of the substances, 5-methylfurfural [FL-no: 13.001], a genotoxicity concern could not be ruled out due to other structural alerts in the substance.

| FGE | Opinion adopted by EFSA | Link | No. of candidate substances |
|------------|--------------------------------|---|------------------------------------|
| FGE.66 | 9 July 2008 | http://www.efsa.europa.eu/EFSA/efsa_locale-1178620753812_1211902338972.htm | 14 |
| FGE.66Rev1 | 6 July 2011 | | 14 |

Additional genotoxicity data have become available for a structurally related substance to 5-methylfurfural [FL-no: 13.001], namely 5-hydroxymethylfurfural [FL-no: 13.139] for which additional genotoxicity data have been requested in FGE.13. It is anticipated that 5-methylfurfural can be oxidised to the primary alcohol 5-hydroxymethylfurfural (EFSA, 2010ak) and accordingly the new data submitted for 5-hydroxymethylfurfural was used in FGE.218Rev1 (EFSA, 2010ak) and will be used in this FGE to support the evaluation of 5-methylfurfural. Therefore the evaluation of these genotoxicity data submitted by the Industry are included in FGE.66Rev1.

Since the publication of FGE.66, the EU production volumes have been provided for three substances [FL-no: 13.003, 13.005 and 13.025], the evaluation of which could not be finalised in the previous version of this FGE, due to lack of these data. Based on the newly submitted EU production volumes these substances have already been evaluated in FGE.96, but for the sake of completion, the information has also been included here as well.

1. Presentation of the Substances in the JECFA Flavouring Group

1.1. Description

1.1.1. JECFA Status

The JECFA has evaluated a group of 14 furfuryl derivatives and one benzofurancarboxaldehyde at their 55th meeting (JECFA, 2001a).

1.1.2. EFSA Considerations

Nine of the substances in the group of furfuryl alcohol and related substances evaluated by the JECFA (JECFA, 2001a) are alpha,beta-unsaturated aldehydes or precursors for alpha,beta-unsaturated aldehydes. As the alpha,beta-unsaturated aldehyde and ketone structures are considered by the Panel to be structural alerts for genotoxicity, these nine substances, i.e. eight substances in FGE.218 (subgroup 4.2 of FGE.19 (EFSA, 2008b)) [FL-no: 13.001, 13.018, 13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] (EFSA, 2009s) and one substance (2-benzofurancarboxaldehyde [FL-no: 13.031]) from subgroup 4.3 of FGE.19 (EFSA, 2008b), have initially been considered with respect to genotoxicity. The Panel concluded that although the eight substances in FGE.218 (EFSA, 2009s) and FGE.218Rev1 (EFSA, 2010ak) have a structural alert for genotoxicity, the data available do not preclude the evaluation of these eight substances through the Procedure (see Section 3.3 to 3.6). For the ninth substance, 2-benzofurancarboxaldehyde [FL-no: 13.031], the Panel concluded that the substance is structurally different from the eight substances in FGE.218 and should be considered separately in subgroup 4.3 from FGE.19 (EFSA, 2008b). This substance will be considered in Revision 1 of FGE.67, together with another structurally related flavouring substance. Accordingly the present FGE.66Rev1 deals with 14 of the 15 substances from the group of furfuryl alcohol and related substances evaluated by JECFA.

Five [FL-no: 13.002, 13.003, 13.005, 13.025, 13.073] of the remaining six substances are esters of furoic acid and the sixth substance [FL-no: 13.038] is not structurally related to furfural. As for this substance, in other FGEs, no related compounds could be found, it will be evaluated in this FGE.

Thus, this FGE deals with in total 14 candidate substances. Thirteen substances in the JECFA flavouring group of furfuryl alcohol and related substances are structurally related to the subgroup of 10 furfuryl derivatives (without sulphur containing substituents) in the group of furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms evaluated by EFSA in FGE.13Rev2 subgroup Ia (EFSA, 2011h). The remaining substance [FL-no: 13.038] is to be evaluated on its own in this FGE.

1.2. Isomers

1.2.1. Status

None of the JECFA evaluated substances in the group of furfuryl alcohol and related substances has a chiral centre or can exist as geometrical isomers.

1.3. Specifications

1.3.1. Status

The JECFA specifications are available for all 14 substances (JECFA, 2000d). See Table 1.

1.3.2. EFSA Considerations

Adequate specifications are available for all 14 substances. .

2. Intake Estimations

2.1. Status

For all substances evaluated through the JECFA Procedure intake data are available for the EU, see Table 3.1.

2.2. EFSA Considerations

For one of the 14 substances, [FL-no: 13.018], the Industry has submitted use levels for normal and maximum use (EC, 2000a; EFA, 2000e). Based on the normal use levels an mTAMDI figure of 9700 microgram/person/day can be calculated (EFSA, 2004d).

Table 2.2.1 Normal and Maximum use levels (mg/kg) available for JECFA evaluated substances in FGE.66Rev1

| FL-no | Food Categories | | | | | | | | | | | | | | | | | |
|--------|----------------------------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|------|
| | Normal use levels (mg/kg) | | | | | | | | | | | | | | | | | |
| | Maximum use levels (mg/kg) | | | | | | | | | | | | | | | | | |
| | 01.0 | 02.0 | 03.0 | 04.1 | 04.2 | 05.0 | 06.0 | 07.0 | 08.0 | 09.0 | 10.0 | 11.0 | 12.0 | 13.0 | 14.1 | 14.2 | 15.0 | 16.0 |
| 13.018 | 25 | - | 25 | | | 25 | 5 | 5 | - | - | - | - | 25 | 25 | 15 | 17 | | |
| | 60 | - | 50 | 0,25 | 0,25 | 700 | 25 | 125 | - | - | - | - | 63 | | 28 | 30 | 25 | 25 |

Table 2.2.2 Estimated intakes based on the MSDI approach and the mTAMDI approach

| FL-no | EU Register name | MSDI – EU (µg/capita/day) | MSDI – USA (µg/capita/day) | mTAMDI (µg/person/day) | Structural class | Threshold of concern (µg/person/day) |
|--------|----------------------------|------------------------------|-------------------------------|---------------------------|---------------------|---|
| 13.001 | 5-Methylfurfural | 180 | 25 | | Class II | 540 |
| 13.002 | Methyl 2-furoate | 30 | 37 | | Class II | 540 |
| 13.003 | Propyl 2-furoate | 0.061 | 0.1 | | Class II | 540 |
| 13.018 | Furfural | 440 | 460 | 9700 | Class II | 540 |
| 13.019 | Furfuryl alcohol | 180 | 24 | | Class II | 540 |
| 13.057 | Furfuryl isovalerate | 0.024 | 1 | | Class II | 540 |
| 13.062 | Furfuryl propionate | 1.7 | 5 | | Class II | 540 |
| 13.068 | Furfuryl valerate | 0.24 | 14 | | Class II | 540 |
| 13.128 | Furfuryl acetate | 16 | 21 | | Class II | 540 |
| 13.005 | Hexyl 2-furoate | 0.061 | 0.1 | | Class III | 90 |
| 13.025 | Pentyl 2-furoate | 0.36 | 0.1 | | Class III | 90 |
| 13.038 | 2-Phenyl-3-carbethoxyfuran | 0.012 | 2 | | Class III | 90 |
| 13.067 | Furfuryl octanoate | 0.012 | 6 | | Class III | 90 |
| 13.073 | Octyl 2-furoate | 2.2 | 0.1 | | Class III | 90 |

3. Genotoxicity Data

3.1. Genotoxicity Studies – Text taken⁴ from the JECFA (JECFA, 2001b)

No genotoxicity text was prepared by the JECFA on the group of furfuryl alcohol and related substances – the studies are only given in table format (see Table 2.1).

⁴ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

3.2. Genotoxicity on furfural – Text taken⁵ from the JECFA (JECFA, 2001b)

One of the substances in the group of furfuryl alcohol and related substances is furfural [FL-no: 13.018], which also was considered separately at the 55th meeting (JECFA, 2001b) where the following was stated:

“Furfural was evaluated previously by the Committee at its thirty-ninth and fifty-first meetings (JECFA, 1992a; JECFA, 2000a). An ADI was not established at either meeting because of concern about the finding of tumours in male mice given furfural in corn oil by gavage and the fact that no NOEL was identified for hepatotoxicity in male rats. In a study in mice, the combined incidence of adenomas and carcinomas was increased in males at the highest dose (175 mg/kg bw per day). In order to address its concern with regard to the formation of liver tumours in mice, the Committee at its fifty-first meeting requested the results of studies of DNA binding or adduct formation *in vivo* to clarify whether furfural interacts with DNA in the liver of mice, and also requested the results of a 90-day toxicity study in rats to identify a NOEL for hepatotoxicity (JECFA, 2000a).

Since the last meeting, the results of a 14-day study to determine a dose range, a 90-day study of toxicity in rats, and an assay for unscheduled DNA synthesis in mice *in vivo* have become available. These data were reviewed and are summarized in the following monograph addendum.”

“The ability of furfural to induce DNA repair in the hepatocytes of B6C3F1 mice was assessed in an assay for unscheduled DNA synthesis. The maximum tolerated dose for animals of each sex was determined in a preliminary study to be 320 mg/kg bw. In the study of unscheduled DNA synthesis, doses of 50, 175, and 320 mg/kg bw were given to groups of three animals of each sex, and expression of DNA repair was measured 2 - 4 and 12 - 16 hours after treatment. N-Nitrosodimethylamine (20 mg/kg bw) was used to measure expression within 2 - 4 hours and aminoazotoluene (200 mg/kg bw) for expression within 12 - 16 hours, as positive controls.

The animals treated with furfural did not show increased unscheduled DNA synthesis at either time after dosing, whereas the positive controls showed statistically significant increases in net nuclear grain counts. Little replicative DNA synthesis (0 - 0.4 %) was seen at either interval. The results provided no evidence that furfural damages DNA in mouse hepatocytes at doses up to 320 mg/kg bw (Edwards, 1999).”

“The results of an assay for unscheduled DNA synthesis in mice *in vivo* were reviewed by the Committee. This study, in which doses of up to 350 mg/kg bw were given, was particularly relevant since it addressed potential DNA repair in the cells in which tumours arose, namely hepatocytes. The negative results obtained in this assay were considered by the Committee to provide evidence that the liver tumours observed in the long-term study in mice were unlikely to have occurred through a genotoxic mechanism. The Committee considered that the concerns raised previously with respect to the liver tumours in mice were adequately addressed by this study and that a study of DNA binding was unnecessary.”

For a summary of *in vitro* / *in vivo* genotoxicity data considered by the JECFA, see Table 2.1.

3.3. Genotoxicity Studies – Text taken⁶ from FGE.13Rev2 (EFSA, 2011h)

Data on *in vitro* genotoxicity were provided for the two candidate substances, 5-hydroxymethylfurfural (5-HMF) [FL-no: 13.139] and furoic acid [FL-no: 13.136] as well as for five supporting substances. Data on *in vivo* genotoxicity were only provided on two of the supporting substances. New genotoxicity data on the candidate substance 5-HMF have become available and will be considered in this revision of FGE.13.

⁵ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

⁶ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

*Candidate substances**5-hydroxymethyl furfural [FL-no: 13.139]*

In the *in vitro* tests, 5-HMF gave negative results in the traditional Ames test in strains TA98, TA100, TA104, TA1535 and TA1537 in five and positive results in two studies. The validity of these two studies could not be assessed. In one of these two studies (Omura et al., 1983) the positive response was observed in strain TA100, but not in TA98 and the mutagenic potential was higher in the absence of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only observed in strain TA100 in the presence of metabolic activation (See Table 2.2 of this FGE). A positive result was obtained also in the Umu assay, although only at high concentrations, resulting in reduced cell viability (Janzowski et al., 2000) and in a Rec assay on *B. subtilis* (Shinohara et al., 1986). In V79 cells, 5-HMF induced a small (although statistically significant) increase in chromosomal aberrations, a reduction in mitotic index and, only at high concentrations, resulting in reduced cell viability, also HPRT mutations (Janzowski et al., 2000). In TK6 human lymphoblast cells, 5-HMF gave negative results in the HPRT and TK assay (Surh and Tannenbaum, 1994).

In an Ames test with TA104 strain upon inclusion of PAPS, a sulphy-group donor, and rat liver cytosol into the experimental model, 5-HMF gave a positive result, suggesting that it can be activated to reactive metabolites following sulphylation, with formation of sulphyate-ester (SMF). Indeed, the mutagenic effect could be partly suppressed by the addition of sulphytransferase inhibitors. In accordance, SMF in TA104 was genotoxic in the absence of any metabolic system (cytotoxicity not specified); the effect was reduced by addition of glutathione (GSH) and GSH-transferases and restored when this latter enzyme was inhibited (Lee et al., 1995b).

The formation of SMF was supported by the detection of an unstable conjugate, which disappeared within 60 minutes, when 5-HMF was incubated with ³⁵S-PAPS and liver cytosol. The exact nature of SMF was not elucidated, but its molecular mass was consistent with that of the sulphyate-ester of 5-HMF (Surh and Tannenbaum, 1994).

When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-resistance), without any metabolic activation, a clear positive response was obtained at concentrations that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human lymphoblasts at the *tk* and *hprt* loci, at concentrations (> 40 microg/ml) reducing cell survival to > 63 %. No genotoxicity was observed with 5-HMF, with its acetate ester or with the sulphylation product of 2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of both a reactive sulphy group and a free aldehyde group.

An assay for primary DNA damage (Comet assay) did not show an effect of 5-HMF in V79 and Caco-2 cells up to cytotoxic concentrations (80 mM). 5-HMF caused a slight but significant increase in DNA single strand breaks in primary rat hepatocytes at cytotoxic levels (40 - 100 mM), whereas in human colon biopsy material the same effect was seen in the absence of cytotoxicity. 5-HMF at non-cytotoxic concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 and rat liver cells. The effect of sulphy conjugation was not directly studied, but since this activity is present at least in primary hepatocytes, it might have contributed to the depletion of GSH and to induction of DNA strand breaks in these cells. However, this study was not considered appropriate to evaluate the possible mutagenic activity of SMF in mammalian cells and consequently of 5-HMF *in vivo* (Janzowski et al., 2000).

To support the genotoxic potential of 5-HMF, some indications for tumorigenic activities of 5-HMF have been obtained with rats and mice. It has been reported that 5-HMF may act as both an initiator and a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et al., 1993; Zang et al., 1993). In addition, induction of skin papillomas has been described after topical application of doses of 10 or 25 micromol 5-HMF to mice (Surh et al., 1994).

“Newly submitted data on 5-hydroxymethylfurfural⁷”

Weak mutagenic activity was reported in *S. typhimurium* TA100 strain in the absence of metabolic activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range of concentrations of 100 - 10,000 micrograms/plate; however, negative results were reported in another study with TA98 and TA100 strains and *E. coli* WP2 uvrA/pKM101 in a range of concentrations of 1,500 - 10,000 micrograms/plate (NTP, 2010c).

At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw/day of 5-HMF via gavage. Slides were scanned to determine the frequency of micronuclei in 1,000 normochromatic erythrocytes (NCEs) in 10 animals per sex per treatment group. In addition, the percentage of polychromatic erythrocytes (PCE) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity. No increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical did not exhibit bone marrow toxicity (NTP, 2010c).

The DNA-damaging potential of 5-HMF was tested *in vitro* in the Comet assay with the following five cell lines with various degree of SULT1A1 expression (Durling et al., 2009): two human lines (Caco-2, no detectable 1A1 activity; HEK293, high 1A1 activity); two cell lines from Chinese hamster (V79, no detectable 1A1 activity and V79-hp-PST, high 1A1 activity) and a one mouse lymphoma line (L5178Y, no detectable activity). The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5-HMF for three hours and subjected to a Comet assay to study DNA damage.

DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant reduction in cell viability (from 11 to 30 %). The concentration of 100 mM is ten times higher than the highest concentration (10 mM or 5000 micrograms/ml) recommended by OECD guidelines for *in vitro* testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 3193 micrograms/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The authors (Durling et al., 2009) concluded that DNA damage induced in all cell lines was unrelated to the expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines (Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5-HMF also in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in V79-hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in extent of DNA-damage could be observed. This would indicate absence of a significant contribution of sulphate conjugation in the DNA-damaging activity of 5-HMF.

These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of SCE in 5-HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) reporting the mutagenicity of 5-HMF in a *S. typhimurium* strain genetically modified and expressing human SULT1A1. According to Durling et al. (2009), the reasons of these discrepancies are unknown; one possibility is the different sensitivity of the COMET assay compared to other systems. Durling et al. (Durling et al., 2009) concluded that other important mechanisms for the observed DNA damage

⁷ An *in vivo* micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited relevance. For these two reasons the study is not further discussed.

should be investigated, but that under the conditions of the test, 5-HMF is a rather weak DNA-damaging agent.

In a new publication by Severin et al. (2010), a dose dependent increase in DNA damage was observed in an COMET assay with HepG2 cells exposed to 5-HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5-HMF. Cytotoxicity was observed at the two highest doses (25 and 36.6 mM), with estimated IC₅₀ of 38 mM. HepG2 cells express both CYP and SULT enzymes. In the same publication no effect of 5-HMF was found in an *in vitro* micronucleous assay in the same cell line exposed to similar doses of HMF (20 hours). HMF was also tested in an Ames test performed according to the OECD guidelines 471. No increase in mutants was observed in *S. typhimurium* strains TA 98, TA 100, TA1535 and TA 1537 exposed to 5-HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no additional PAPS was added to the test system (Severin et al., 2010).

However, while 5-HMF was unable to induce micronuclei *in vivo*, in the NTP 3-months study in mice by gavage, and *in vitro*, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice ((Dahlberg, 2004) as cited by Glatt and Sommer, 2006 (no further data were available)).

According to Glatt and Sommer, incubation of DNA with SMF in a cell-free system led to the formation of DNA adducts that could be detected by the ³²P-postlabelling technique. No adducts were formed in incubations with 5-HMF instead of SMF. In subsequent experiments, the authors searched for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells treated with 5-HMF. Although mutations were induced, adducts were not seen in these cells under the same conditions. The authors hypothesized that the lack of DNA adducts might be due to technical problems, since generally DNA adducts are a more sensitive endpoint than mutations as observed with many other compounds (Glatt and Sommer, 2006).

In conclusion, with respect to the genotoxicity 5-HMF, taking into account additional data on metabolism, the following picture emerges. The substance is negative in the conventional Ames test. Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into the metabolic system, suggesting the formation of a sulphate-ester (SMF). In accordance, SMF was mutagenic in the absence of any metabolic activation system. In an *in vitro* assay, 5-HMF induced dose-dependent increase in DNA damage (Comet assay), but this study has major drawbacks and inconsistencies and has to be considered of limited validity. A major limit is the use of too high concentrations that can produce unpredictable effects, not related to the real genotoxic potential of 5-HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) in the same cell system. *In vivo*, a non-standard micronucleus assay in peripheral blood erythrocytes associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this study has limited validity since no bone marrow cell toxicity was observed.

Metabolic studies indicate that *in vivo*, in mice B6C3F1 and rats, the principal route of metabolism is oxidation of 5-HFM to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that SMF has been detected in plasma from animals given 5-HMF, intravenously. This indicates that there is a competition for the substrate 5-HMF between the oxidation pathway leading to the furoic acid derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, the half life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to reach the bone marrow and give any positive effect in an *in vivo* micronucleous test, taking into account that SMF will most likely be formed in the liver. However, 5-HMF has been found unable to

induce micronuclei also *in vitro*, using the HepG2 human cell line, expressing both CYP and SULT enzymes. In the rodents bioassays no carcinogenic response was observed and from this it may be concluded that the formation of the SMF metabolite is too low to result in a carcinogenic response. Assuming that in humans the ratio between the two competing pathways is not more favourable for the formation of SMF than in rodents, no genotoxicity or carcinogenicity is expected in humans either.”

Furoic acid [FL-no: 13.136]

Furoic acid gave negative results in three studies in the Ames test in strains TA98 and TA100. Furoic acid was also negative in DNA repair test in *E. coli* and in an UDS assay using primary rat hepatocytes.

Supporting substances

In vitro genotoxicity data were available for five supporting substances (furfuryl acetate, furfuryl alcohol, furfural, 5-methylfurfural and methyl-2-furoate) and *in vivo* genotoxicity data for the two supporting substances furfuryl alcohol and furfural. Most studies were negative, although some positive results were reported. However, the genotoxicity of furfural has recently been re-evaluated by the AFC Panel, which concluded that furfural did not induce gene mutations *in vivo*, on the basis of new studies with transgenic mice (EFSA, 2004c).

Overall, the genotoxicity data available on the candidate furoic acid and on the supporting substances do not give rise to concern with respect to genotoxicity of nine candidate furfural-related candidate substances included in subgroup Ia [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133 and 13.136]. Based on newly submitted data on the mutagenic activity of 5-HMF [FL-no: 13.139] the concern for genotoxicity which was raised because of genotoxic properties of one of its metabolites (SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate substances in subgroup Ia of FGE.13Rev2, which could preclude their evaluation through the Procedure.

For a summary of *in vitro* / *in vivo* genotoxicity data considered by EFSA, see Table 2.2 and 2.3.

3.4. SCF Opinion on Furfural and Furfural Diethylacetal⁸ (SCF, 2003a)

“Special studies on genotoxicity

Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In particular, positive results were obtained in three out of several assays for reverse mutation in *S. typhimurium* at relatively high concentrations in the absence of metabolic activation. Furfural was found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome level in the absence of metabolic activation. It induced SCE in cultured CHO cells and human lymphocytes. It was genotoxic in *Drosophila* in somatic cells (Wing spot test by inhalation) and germ cells (sex-chromosome loss by injection). It did not induce reciprocal translocations and sex-linked recessive lethal mutations, with only a doubtful increase in one study in *Drosophila*. Furfural was not genotoxic in any *in vivo* mammalian assays for chromosome aberrations, SCE or UDS.”

Conclusion

“The Committee was of the opinion that the data were not totally convincing in demonstrating that the carcinogenicity of furfural was mediated via a thresholded mechanism and hence was unable to allocate an ADI to furfural at the present time. It was aware that a study in transgenic mice of the potential of furfural to induce gene mutations *in vivo* was in progress. The results were expected to be

⁸ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

available in the near future and the Committee would wish to re-evaluate furfural in the light of the results of this study.”

The results of genotoxicity studies on furfural are summarised in Table 2.4.

3.5. EFSA Opinion on Furfural and Furfural Diethylacetal⁹ (EFSA, 2004c)

“Special Studies on Genotoxicity

In a new study not previously evaluated by the SCF, furfural was examined for its potential to induce gene mutations of the λ lacZ-gene *in vivo* in the liver of male transgenic mice (CD2F1(BALB/c x DBA/2) strain 40.6, with lacZ-genes as reporter genes). The study was carried out under GLP. As formal technical guidelines for this type of study are not available, the study protocol was designed in conformity with principles for transgenic studies identified by international expert groups (Gorelick and Mirsalis, 1996; Heddle et al., 2000). The study was conducted in five groups, three of which received furfural by gavage in corn oil, one negative control group received vehicle alone and one positive control group received ethylnitrosourea (ENU). The furfural and negative control groups each comprised 13 mice plus 2 back up animals; the positive control group comprised 8 mice plus 2 reserves. The furfural groups were given doses of 75, 150 or 300 mg furfural/kg bw in corn oil by gavage for 28 consecutive days; ENU was given to the positive control group by intraperitoneal injection in saline on days 5 - 9 of the study at a dose of 50 mg/kg bw/day. On day 28, three animals from each of the furfural and negative control groups were sacrificed for assessment of hepatotoxicity by clinical chemistry and histological examination. In addition, organ and body weights were monitored throughout. After a manifestation period of 34 - 35 days (days 62 - 63 of the study), the livers and samples of gastrointestinal tract tissues were fixed for mutation analysis. Mutation analysis was carried out on the livers of eight animals per group. At least 5000 (preferably 120,000) plaque-forming units (PFU) were examined (one PFU corresponding to one recovered copy of the λ gt10lacZ shuttle vector).

There were three early decedents in the highest furfural dose group; two during treatment with no clinical signs, and one during the manifestation period. One animal from the low-dose group died during the manifestation period. The cause of death could not be ascertained.

Body weights in the furfural-treated groups showed a dose related increase compared to negative controls during the first week of treatment. In the post-treatment period the difference between control and two lower dose groups disappeared but the body weight of the group treated with 300 mg furfural/kg bw remained higher.

Evaluation of the clinical chemistry and gross and histopathology of the liver of the treated animals sacrificed at the end of the treatment period showed an increase in blood triglycerides, increased liver weight and centrilobular hypertrophy. This was interpreted by the authors as some evidence of hepatotoxicity. These changes did not persist until the end of the manifestation period, 34 - 35 days after the last dose.

The mutation frequency in DNA extracted from the livers of the negative control group was similar to historical data. There was no significant difference in mutation frequency between negative controls and the furfural-treated groups; the positive control group showed a significant increase in mutation frequency. It was concluded that oral administration of furfural in corn oil at levels of up to 300 mg/kg bw/day is not associated with an increase in the induction of mutations in liver cells of λ lacZ transgenic mice (CIVO-TNO, 2003).

⁹ The text is taken verbatim from the indicated reference source, but text related to substances not included in the present FGE has been removed.

Negative or weakly positive results have been obtained for most bacterial tests for genotoxicity. In particular, positive results were obtained in three out of several assays for reverse mutation in *Salmonella typhimurium* at relatively high concentrations in the absence of metabolic activation. Furfural was found to be clearly genotoxic in cultured mammalian cells at the gene and chromosome level in the absence of metabolic activation. It induced Sister Chromatid Exchange (SCE) in cultured Chinese Hamster Ovary (CHO) cells and human lymphocytes. It was genotoxic in *Drosophila* in somatic cells (Wing spot test by inhalation) and germ cells (sex-chromosome loss by injection). It did not induce reciprocal translocations and sex-linked recessive lethal mutations, with only a doubtful increase in one study in *Drosophila*. Furfural was not genotoxic in any *in vivo* mammalian assays for chromosome aberrations, SCE or Unscheduled DNA Synthesis (UDS) and the study in transgenic mice confirms that furfural does not induce gene mutations *in vivo*.

Discussion

The Panel noted the metabolic and toxicity data previously reviewed by the SCF together with the new results of the genotoxicity study in transgenic mice *in vivo*.

Furfural was negative in the *in vivo* genotoxicity assay and this corroborated earlier negative *in vivo* studies at the chromosome level and in a UDS assay.

In view of the absence of genotoxicity *in vivo*, the tumours observed in the long-term toxicity/carcinogenicity studies in male, but not female mice, are considered to arise as a consequence of chronic hepatotoxicity (hepatocellular necrosis) which was more marked in male animals. An increased tumour incidence was only observed at the highest dose level and at a dose higher than the minimal hepatotoxic dose.

It should be noted that no hepatocellular tumours were seen in the long-term rat study. However, liver toxicity was seen in this study (see SCF Opinion, Appendix 1) and the rat was considered more sensitive to liver toxicity.

The hepatotoxicity of furfural is dose-dependent but a NOEL was not established in the long-term studies. However, the short-term (90-day) study in rats was conducted to establish a NOEL for hepatotoxicity, which was determined to be 54 mg/kg bw. The Panel noted that because of possible formulation (corn oil) and dose regimen (bolus dose) effects observed in the gavage studies, the dietary administration studies were more appropriate for identifying a NOAEL. The Panel concluded that the NOAEL of 54 mg/kg bw/day for hepatic changes from the 90 day dietary study was appropriate and noted that the effects observed with doses up to threefold higher were of doubtful toxicological relevance. Therefore the Panel concluded that a safety factor of 100 would be sufficient in establishing an ADI from this subchronic study (see SCF Opinion).

Conclusion and Recommendation

The Panel concluded that furfural did not exhibit genotoxicity *in vivo* in male mice, the species and sex which displayed an increased tumour incidence in long-term studies and that the tumours arose by a secondary mechanism consequent on hepatotoxicity, which is dose dependent, displays a threshold and is seen in both rats and mice. It was therefore considered that the NOEL for hepatotoxicity in the rat could be used to derive an ADI for furfural.

An ADI for furfural was established at 0.5 mg/kg bw based on the NOEL of 54 mg/kg bw from the 90-day rat study to which a 100-fold safety factor was applied. Since furfural diethylacetal is rapidly converted to furfural at physiological pH, the ADI applies also to the furfural component of furfural diethylacetal since furfural is readily liberated from the acetal *in vivo*.”

3.6. EFSA Considerations

In the evaluation of the genotoxic potential of the substances in FGE.218 (EFSA, 2009s), the Panel has taken into consideration the SCF Opinion expressed in December 2002 on furfural and furfural diethylacetal (SCF, 2003a) (See Section 3.4). This Opinion was later updated by EFSA in June 2004 (EFSA, 2004c) with consideration of additional data on the potential genotoxicity of furfural (See Section 3.5). Furthermore the evaluation by the JECFA on furfural and furfuryl alcohol and related flavouring agents at its 55th meeting (JECFA, 2001b) has been considered by the Panel (See Section 3.1 and 3.2).

The Panel concluded that the data available on seven of the eight substances in FGE.218 [FL-no: 13.018, 13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] do not preclude the evaluation of these substances through the Procedure. Therefore, they can be evaluated together with the other six substances [FL-no: 13.002, 13.003, 13.005, 13.025, 13.038 and 13.073] from the JECFA group of furfuryl alcohol and related substances (JECFA, 2001b). 5-Methylfurfural [FL-no: 13.001] can be oxidised in the 5-methyl-group of the hetero-aromatic system to form 5-hydroxymethylfurfuraldehyde [FL-no: 13.139]. In FGE.13 (EFSA, 2005c), it was concluded that 5-hydroxymethylfurfuraldehyde may be metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic potential *in vitro* and that the Procedure could not be applied for this substance. However, after the publication of FGE.13 sufficient data have been provided to mitigate this concern with respect to genotoxic potential of [FL-no: 13.139] *in vivo* (EFSA, 2011h) and accordingly there is no concern for 5-methylfurfural [FL-no: 13.001], as concluded in FGE.218Rev1 (EFSA, 2010ak). So, the Panel agrees with JECFA that [FL-no: 13.001] may also be evaluated using the Procedure.

4. Application of the Procedure

4.1. Application of the Procedure to Furfuryl Alcohol and Related Substances, Text taken from the JECFA (JECFA, 2001b)

Step 1

In applying the Procedure for the safety evaluation of flavouring substances, the JECFA assigned nine of the 14 substances in this consideration [FL-no: 13.001, 13.002, 13.003, 13.018, 13.019, 13.057, 13.062, 13.068 and 13.128] to structural class II (Cramer et al., 1978). Furfuryl propionate [FL-no: 13.062] was assigned to this class because it is structurally closely related to furfuryl acetate [FL-no: 13.128] and furfuryl pentanoate [FL-no: 13.068]. The remaining five substances [FL-no: 13.005, 13.025, 13.038, 13.067 and 13.073] were assigned to structural class III.

Step 2

The data on the metabolism of individual members of the group were sufficient to draw conclusions about their probable metabolic fate. Most substances ([FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128]) are predicted to be metabolised to 2-furoic acid or a 2-furoic acid derivative, which is either conjugated with glycine and excreted in the urine or condensed with acetyl CoA and conjugated with glycine before excretion in the urine. Because of concern about the results of the toxicological studies on furfural in rodents, these substances cannot be predicted to be metabolised to innocuous products. The evaluation of all substances in this group therefore proceeded via the B-side of the scheme.

Step 3

The estimated daily per capita intakes of all 14 substances in this group are below the threshold of concern for the respective structural classes (i.e. 540 µg/day for structural class II and 90 µg/day for structural class III). Accordingly, the evaluation of all 14 substances in the group proceeded to step B4.

Step 4

For furfural, the NOEL of 53 mg/kg bw/day in a 13-week feeding study in rats (Jonker, 2000b) provides an adequate margin of safety (> 1000 times) in relation to the known levels of intake of this substance. This NOEL is also appropriate for furfuryl alcohol [FL-no: 13.019] and the structurally related substances furfuryl acetate [FL-no: 13.128], furfuryl propionate [FL-no: 13.062], furfuryl pentanoate [FL-no: 13.068], furfuryl octanoate [FL-no: 13.067] and furfuryl 3-methylbutanoate [FL-no: 13.057], because all of these esters would be hydrolysed to furfuryl alcohol [FL-no: 13.019] and then oxidised to furfural [FL-no: 13.018]. The NOEL for furfural is also appropriate for the esters of furoic acid, methyl 2-furoate [FL-no: 13.002], propyl 2-furoate [FL-no: 13.003], amyl 2-furoate [FL-no: 13.025], hexyl 2-furoate [FL-no: 13.005] and octyl 2-furoate [FL-no: 13.073], which would be hydrolysed to furoic acid, the major metabolite of furfural. The NOEL for furfural is also appropriate for 5-methylfurfural [FL-no: 13.001], which would participate in the same metabolic pathways and also undergo alkyl oxidation. For 2-phenyl-3-carbethoxyfuran [FL-no: 13.038], the NOEL of 13 mg/kg bw/day in a 90-day feeding study in rats (Posternak et al., 1969) provides an adequate margin of safety (> 1000 times) in relation to the known levels of intake of this substance.

The evaluation of the 14 substances are summarised in Table 3.1: Summary of Safety Evaluation of Furfuryl Derivatives (JECFA, 2001b).

4.2. Application of the Procedure to a Group of Furfuryl and Furan Derivatives with and without Additional Side-Chain Substituents and Heteroatoms Evaluated by EFSA, Text taken from FGE.13Rev2 (EFSA, 2011h)

Only text relevant for substances in FGE.66Rev1 has been cited from the Procedure in FGE.13Rev2

One of the 10 candidate substances, 5-hydroxymethylfurfuraldehyde [FL-no: 13.139], may be metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic potential *in vitro*. Sufficient data have been provided to mitigate this concern with respect to genotoxic potential *in vivo*.

For the safety evaluation of the 10 candidate substances from subgroup Ia of FGE.13Rev2 the Procedure as outlined in Annex I was applied. The stepwise evaluations of the 10 substances are summarised in Table 3.2.

Step 1

According to the decision tree approach by Cramer et al. (Cramer et al., 1978) four candidate substances are classified into structural class II [FL-no: 13.122, 13.130, 13.136 and 13.139] and six substances are classified into structural class III [FL-no: 13.011, 13.102, 13.127, 13.129, 13.132 and 13.133].

Step 2

None of the candidate substances is predicted to be metabolised to innocuous products. Therefore, the evaluation of the 10 candidate substances proceeds via the B-side of the evaluation scheme.

Step B3

Four candidate substances, have been assigned to structural class II, and have estimated European daily *per capita* intakes (MSDI) ranging from 0.013 to 0.39 microgram (Table 3.2). These intakes are below the threshold of concern of 540 microgram/person/day for structural class II. Six candidate substances have been assigned to structural class III, and have estimated European daily *per capita* intakes (MSDI) ranging from 0.11 to 0.89 microgram (Table 3.2). These intakes are below the threshold of concern of 90 microgram/person/day for structural class III. Therefore, the safety evaluation proceeds to step B4 for all 10 candidate substances.

Step B4

Considering that the 10 candidate substances are metabolised to yield furfural and furoic acid or furanacrylic acid, the toxicity of the esters of furfuryl alcohol [FL-no: 13.127, 13.129, 13.130, 13.132, and 13.133], furoic acid [FL-no: 13.102 and 13.122] and furanacrylic acid [FL-no: 13.011] is expected to be similar to that of the structurally related supporting substance furfural [FL-no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major metabolite of furfural. For furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg bw has recently been established by EFSA (EFSA, 2004c). The estimated daily *per capita* intakes based on the MSDI approach expressed in microgram/kg body weight (bw)/day of candidate substances in subgroup Ia of the present FGE.13Rev2 are more than 30.000 fold below the ADI value.

For 5-HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 13-week subchronic studies and chronic studies in B6C3F1 mice and F344/N rats (NTP, 2010c). The carcinogenicity study in mice demonstrated that 5-HMF may induce liver tumours, but these are considered irrelevant for humans. In contrast, no carcinogenic responses have been reported in the study with rats. The data have shown that the critical effect is cytoplasmic alterations in renal proximal tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw/day for 5 days/week and above with an intermittent dose regimen of five days per week. For this effects a Benchmark Dose, Lower Confidence Limit (BMDL) of 20.2 mg/kg bw for 5 days/week can be derived, which would be equivalent to 14.4 mg/kg bw/day, when corrected for continuous daily administration. When this BMDL of 14.4 mg/kg bw/day derived from the 13-weeks study in mice is compared to the MSDI of 0.39 microgram/*capita*/day for this substance, a margin of safety of 2.2×10^6 can be calculated. From this it is concluded that 5-HMF [FL-no: 13.139] does not raise a safety concern as a flavouring substance, at its current level of use in foods.

In summary, it can be concluded at step B4 of the Procedure that the 10 candidate substances included in FGE.13Rev2 pose no safety concern when they are used as flavouring substances at the estimated levels of daily *per capita* intake based on the MSDI approach.

The stepwise evaluations of the 10 substances are summarised in Table 3.2: Summary of Safety Evaluation Applying the Procedure (EFSA / FGE.13Rev2)

4.3. EFSA Considerations

The Panel agrees with the application of the Procedure as performed by the JECFA for 13 of the 14 substances in the group of furfuryl alcohol and related substances considered in this FGE. For 5-methylfurfural [FL-no: 13.001] it is anticipated that the 5-methylgroup can be oxidised to the primary alcohol 5-hydroxymethylfurfural [FL-no: 13.139]. In FGE.13 it was concluded that 5-hydroxymethylfurfural may be metabolised to 5-[(sulphoxy)methyl]furfural, which shows genotoxic potential *in vitro* and could therefore not be evaluated through the Procedure (EFSA, 2005c). However, after the publication of FGE.13, sufficient data have been provided to mitigate this concern with respect to genotoxic potential *in vivo* (EFSA, 2011h), and the Panel can agree to evaluate [FL-no: 13.001] according to the Procedure. The Panel concluded it more appropriate to evaluate the exposure estimate of 180 microgram/*capita*/day (MSDI) for 5-methylfurfural [FL-no: 13.001] against the BMDL of 14.4 mg/kg bw/day derived in FGE.13Rev2 for 5-hydroxymethylfurfural [FL-no: 13.139]. For 5-methylfurfural an adequate Margin of Safety of 4800 can be calculated. So, the Panel can agree in the outcome of the Procedure as performed by the JECFA for [FL-no: 13.001] as well.

In the previous version of FGE.66, for three substances [FL-no: 13.003, 13.005 and 13.025] no European production figures were available and no MSDI could be calculated at the time where FGE.66 was published. Consequently the safety in use could not be assessed using the Procedure based on the MSDI approach for these three substances. Since the publication of FGE.66, the EU production volumes have been provided for these three substances. For all three substances [FL-no: 13.003, 13.005 and 13.025], which were evaluated via the B-side of the Procedure, an adequate

margin of safety could be calculated using the NOAEL for the structurally related furfural [FL-no: 13.018]. Therefore the Panel concluded at step B4 that these substances would be of no safety concern at their estimated levels of intake based on the MSDI approach (EFSA, 2010aj).

5. Conclusion

The JECFA has evaluated 15 furfuryl alcohol derivatives at their 55th meeting. The Panel concluded that 14 substances in FGE.66 are structurally related to the subgroup of 10 furfuryl derivatives in the group of furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms evaluated by EFSA in FGE.13Rev2. The 15th substance [FL-no: 13.031] is considered too structurally different from the other 14 to be included in the present FGE. This substance will be evaluated in FGE.67.

Eight of the candidate substances in this FGE are alpha,beta-unsaturated aldehydes or precursors for such which is a structural alert for genotoxicity. These eight substances [FL-no: 13.001, 13.018, 13.019, 13.057, 13.062, 13.067, 13.068 and 13.128] have initially been considered with respect to genotoxicity. The Panel concluded that for all eight substances, the genotoxicity data available do not preclude their evaluation through the Procedure. No concern for genotoxicity was identified for the remaining six substances without the alpha,beta structural alert [FL-no: 13.002, 13.003, 13.005, 13.025, 13.038 and 13.073].

The Panel agrees with the application of the Procedure as performed by the JECFA for 13 substances considered in this FGE [FL-no: 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128]. In contrast to the JECFA, the Panel evaluated the fourteenth substance [FL-no: 13.001] by comparison with a BMDL for a metabolite (5-hydroxymethylfurfural; [FL-no: 13.139]). For none of the candidate substances in this FGE a safety concern was identified.

For 13 substances [FL-no: 13.001, 13.002, 13.003, 13.005, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] use levels are needed to calculate the mTAMDI in order to identify those flavouring substances that need more refined exposure assessment and to finalise the evaluation. For one substance, furfural [FL-no: 13.018] use levels have been provided by Industry and an mTAMDI figure of 9700 microgram/person/day could be calculated.

In order to determine whether the conclusion for the substances considered in this FGE can be applied to the materials of commerce, it is necessary to consider the available specifications. Adequate specifications including purity criteria and identity test are available for all 14 JECFA evaluated substances considered in the present FGE.

Thus, for all 14 JECFA evaluated furfuryl derivatives [FL-no: 13.001, 13.002, 13.003, 13.005, 13.018, 13.019, 13.025, 13.038, 13.057, 13.062, 13.067, 13.068, 13.073 and 13.128] the Panel agrees with the JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances” based on the MSDI approach.

TABLE 1: SPECIFICATION SUMMARY

Table 1: Specification Summary of the Substances in the Group of furfuryl alcohol and related flavouring substances evaluated by the JECFA (JECFA, 2000d)















| FL-no JECFA-no | EU Register name | Structural formula | FEMA no CoE no CAS no | Phys.form Mol.formula Mol.weight | Solubility 1) Solubility in ethanol 2) | Boiling point, °C 3) Melting point, °C ID test Assay minimum | Refrac. Index 4) Spec.gravity 5) |
|-------------------|----------------------------|---|-----------------------------|--|---|---|-------------------------------------|
| 13.001 745 | 5-Methylfurfural |  | 2702 119 620-02-0 | Liquid C ₆ H ₆ O ₂ 110.11 | Slightly soluble Miscible | 187 IR 97 % | 1.525-1.532 1.098-1.108 |
| 13.002 746 | Methyl 2-furoate |  | 2703 358 611-13-2 | Liquid C ₆ H ₆ O ₃ 126.11 | Insoluble to slightly soluble Miscible | 181 IR 98 % | 1.485-1.490 1.176-1.181 |
| 13.003 747 | Propyl 2-furoate |  | 2946 359 615-10-1 | Liquid C ₈ H ₁₀ O ₃ 154.17 | Slightly soluble Miscible | 211 MS 97 % | 1.471-1.475 1.067-1.075 |
| 13.005 749 | Hexyl 2-furoate |  | 2571 361 39251-86-0 | Liquid C ₁₁ H ₁₆ O ₃ 196.25 | Insoluble Miscible | 252 IR 97 % | 1.468-1.473 1.015-1.020 |
| 13.018 450 | Furfural |  | 2489 2014 98-01-1 | Liquid C ₅ H ₄ O ₂ 96.10 | soluble miscible | 161-162 IR 95 % | 1.521-1.529 1.153-1.162 |
| 13.019 451 | Furfuryl alcohol |  | 2491 2023 98-00-0 | Liquid C ₅ H ₆ O ₂ 98.1 | miscible miscible | 169-171 IR 97 % | 1.481-1.489 1.126-1.136 |
| 13.025 748 | Pentyl 2-furoate |  | 2072 2109 1334-82-3 | Liquid C ₁₀ H ₁₄ O ₃ 182.22 | Insoluble Miscible | 95-97 (1.3 hPa) IR 98 % | 1.469-1.475 1.031-1.038 |
| 13.038 752 | 2-Phenyl-3-carbethoxyfuran |  | 3468 2309 50626-02-3 | Liquid C ₁₃ H ₁₂ O ₃ 216.24 | Slightly soluble Miscible | 148-154 (8 hPa) IR 99 % | 1.515-1.527 1.120-1.132 |
| 13.057 743 | Furfuryl isovalerate |  | 3283 10642 13678-60-9 | Liquid C ₁₀ H ₁₄ O ₃ 182.22 | Insoluble Miscible | 97-98 (14 hPa) IR 98 % | 1.456-1.464 1.014-1.023 |
| 13.062 740 | Furfuryl propionate |  | 3346 10646 623-19-8 | Liquid C ₈ H ₁₀ O ₃ 154.17 | Slightly soluble Miscible | 195-196 IR 98 % | 1.457-1.464 1.076-1.086 |

Table 1: Specification Summary of the Substances in the Group of furfuryl alcohol and related flavouring substances evaluated by the JECFA (JECFA, 2000d)

| FL-no JECFA-no | EU Register name | Structural formula | FEMA no CoE no CAS no | Phys.form Mol.formula Mol.weight | Solubility 1) Solubility in ethanol 2) | Boiling point, °C 3) Melting point, °C ID test Assay minimum | Refrac. Index 4) Spec.gravity 5) |
|-------------------|--------------------|---|-----------------------------|--|---|---|-------------------------------------|
| 13.067 742 | Furfuryl octanoate |  | 3396 10645 39252-03-4 | Liquid C ₁₃ H ₂₀ O ₃ 224.30 | Insoluble Miscible | 139 (13 hPa) IR 98 % | 1.456-1.464 0.980-0.989 |
| 13.068 741 | Furfuryl valerate |  | 3397 10647 36701-01-6 | Liquid C ₁₀ H ₁₄ O ₃ 182.22 | Insoluble Miscible | 228-229 IR 98 % | 1.457-1.462 1.024-1.031 |
| 13.073 750 | Octyl 2-furoate |  | 3518 10864 39251-88-2 | Liquid C ₁₃ H ₂₀ O ₃ 224.30 | Insoluble Miscible | 126-127 (1 hPa) IR 98 % | 1.466-1.472 0.984-0.990 |
| 13.128 739 | Furfuryl acetate |  | 2490 2065 623-17-6 | Liquid C ₇ H ₈ O ₃ 140.14 | Insoluble Miscible | 175-177 IR 97 % | 1.457-1.466 1.110-1.119 |

- 1) Solubility in water, if not otherwise stated.
 2) Solubility in 95 % ethanol, if not otherwise stated.
 3) At 1013.25 hPa, if not otherwise stated.
 4) At 20°C, if not otherwise stated.
 5) At 25°C, if not otherwise stated.

TABLE 2: GENOTOXICITY DATA

Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b)




| FL-no JECFA-no | EU Register name JECFA name | Structural formula | End-point | Test system | Concentration | Results | Reference |
|-------------------|--------------------------------|---|--------------------------------------|--|--|---|---------------------------------|
| 13.019 451 | Furfuryl alcohol |  | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 | 294 µg/plate | Negative ^{a,b} | (Florin et al., 1980) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA1535 | Up to 10 000 µg/plate | Negative ^{a,b} | (Mortelmans et al., 1986) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100 | 2500 - 12 500 µg/ml | Negative ^{a,b} | (Stich et al., 1981a) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA102 | Up to 198 000 µg/plate | Negative ^{a,b} | (Aeschbacher et al., 1989) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100 | 81 - 323 µg/plate | Negative ^{a,b} | (Shinohara et al., 1986) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA1535, TA100, TA1537 (modified assay) | 200 000 µg/ml | Positive ^{a,b} | (McGregor et al., 1981) |
| | | | DNA repair and H17 (rec+) | <i>B. subtilis</i> M45 (rec-) | 2000 - 20 000 µg/disc | Positive ^{a,b} | (Shinohara et al., 1986) |
| | | | Sister chromatid exchange | Chinese hamster ovary cells | 245 µg/ml | Positive ^{a,b} | (Stich et al., 1981b) |
| | | | Sister chromatid exchange | Human lymphocytes | Up to 196 µg/ml | Negative | (Jansson et al., 1986) |
| | | | Sister chromatid exchange | Human lymphocytes | Up to 970 µg/ml | Negative | (Gomez-Arroyo and Souza, 1985) |
| | | | Chromosomal aberration | Chinese hamster ovary cells | 2000 µg/ml | Positive | (Stich et al., 1981b) |
| | | | Gene conversion | <i>S. cerevisiae</i> strain D7 | 13 500 - 16 000 µg/ml | Positive ^a | (Stich et al., 1981a) |
| | | | Sex-linked recessive lethal mutation | <i>D. melanogaster</i> | Up to 6500 ppm by injection | Negative | (Rodriguez-Arnaiz et al., 1989) |
| | | | Sister chromatid exchange | Adult human lymphocytes | 32 300 mg/m ³ in occupational atmosphere | Negative | (Gomez-Arroyo and Souza, 1985) |
| | | | Sister chromatid exchange | Adult human lymphocytes | 32 300 mg/m ³ in occupational atmosphere | Negative | (Gomez-Arroyo and Souza, 1985) |
| | | | Chromosomal aberration | Mouse bone-marrow cells | 0.5 mg/kg bw in drinking-water 1 - 2 mg/kg bw in drinking-water | Negative Positive | (Sujatha and Subramanyam, 1994) |
| 13.128 739 | Furfuryl acetate |  | Reverse mutation | <i>S. typhimurium</i> TA1535, TA98, TA100 | 33 - 666 µg/plate | Positive ^{a,b} | (Mortelmans et al., 1986) |
| 13.018 450 | Furfural |  | Reverse mutation | <i>S. typhimurium</i> TA1535, TA100, TA1537, TA1538, TA98 | 0.1 - 1000 µg/ml | Negative ^{a,b} | (McMahon et al., 1979) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA98, TA1535 | Up to 3460 µg/plate 5766 µg/plate | Negative ^{a,b} Positive ^a (weakly) | (Loquet et al., 1981) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA98, TA102 | Up to 115 320 µg/plate | Negative ^{a,b} | (Aeschbacher et al., 1989) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA98 | 15 - 63 µg/plate | Negative ^{a,b} | (Shinohara et al., 1986) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA104 | 5 - 500 µg/plate | Positive ^b | (Shane et al., 1988) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA102 | 5 - 500 µg/plate | Negative ^b | (Shane et al., 1988) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA104, TA102 | 96 µg/plate | Negative | (Marnett et al., 1985a) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA1535 | Up to 6667 µg/plate | Negative ^{a,b} | (Mortelmans et al., 1986) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100 | Up to 1000 µg | Negative ^a | (Osawa and Namiki, 1982) |

Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b)




| FL-no JECFA-no | EU Register name JECFA name | Structural formula | End-point | Test system | Concentration | Results | Reference |
|-------------------|---|--------------------|--------------------------------------|--|--|--|---------------------------------|
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 | 33 - 6666 µg/plate | Negative ^{a,b} Equivocal in TA100 ^a | (NTP, 1990a) |
| Furfural (cont.) |  | | Reverse mutation | <i>S. typhimurium</i> TA100 | 8000 µg/plate | Positive ^{a,b} | (Zdzienicka et al., 1978) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98 | 8000 µg/plate | Negative ^{a,b} | (Zdzienicka et al., 1978) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA102 | 100 - 10 000 µg/plate | Negative ^a | (Dillon et al., 1998) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA104 | 100 - 10 000 µg/plate | Equivocal ^a | (Dillon et al., 1998) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA102, TA104 | 100 - 10 000 µg/plate | Negative ^b | (Dillon et al., 1998) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100 | 100 - 10 000 µg/plate | Equivocal ^b | (Dillon et al., 1998) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100 (modified assay) | 426 µg/plate | Negative ^{a,b} | (Kim et al., 1987b) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA100, TA1535, TA1537 (modified assay) | 200 000 µg/ml | Negative | (McGregor et al., 1981) |
| | | | Reverse mutation | <i>E. coli</i> WP2, WP2 uvrA (modified assay) | 0.1 - 1000 µg/ml | Negative ^{a,b} | (McMahon et al., 1979) |
| | | | SOS induction | <i>S. typhimurium</i> TA1535/ pSK1002 | 1932 µg/ml | Negative ^{a,b} | (Nakamura et al., 1987) |
| | | | DNA repair | <i>B. subtilis</i> H17 (rec+) and M45 (rec-) | Up to 1000 µg | Negative ^a | (Osawa and Namiki, 1982) |
| | | | DNA repair | <i>B. subtilis</i> H17 (rec+) and M45 (rec-) | 0.6 ml | Negative ^{a,b} | (Matsui et al., 1989) |
| | | | DNA repair | <i>B. subtilis</i> H17 (rec+) and M45 (rec-) | 1700 - 17 000 µg/disc | Positive ^{a,b} | (Shinohara et al., 1986) |
| | | | Forward mutation | L5178Y mouse lymphoma cells, Tk+/- locus | 25 - 100 µg/ml 200 µg/ml | Negative ^a Positive ^a | (McGregor et al., 1988b) |
| | | | Sister chromatid exchange | Chinese hamster ovary cells | 2500 - 4000 µg/ml | Positive ^{a,b} | (Stich et al., 1981b) |
| | | | Sister chromatid exchange | Chinese hamster ovary cells | Up to 1170 µg/ml | Positive ^{a,b} | (NTP, 1990a) |
| | | | Sister chromatid exchange | Human lymphocytes | Up to 0.035 mmol/L ^a 0.07 - 0.14 mmol/L ^c | Negative ^{a,b} Positive ^{a,b} | (Gomez-Arroyo and Souza, 1985) |
| | | | Chromosomal aberration | Chinese hamster ovary cells | 500 µg/ml 1000 - 2000 µg/ml | Negative Positive | (Nishi et al., 1989) |
| | | | Chromosomal aberration | Chinese hamster ovary cells | Up to 40 mmol/L (3840 mg) | Positive ^{a,b} | (Stich et al., 1981b) |
| | | | Chromosomal aberration | Chinese hamster ovary cells | 3000 µg/ml | Positive | (Stich et al., 1981a) |
| | | | Chromosomal aberration | Chinese hamster ovary cells | Up to 1230 µg/ml | Positive ^{a,b} | (NTP, 1990a) |
| | | | Unscheduled DNA synthesis | Human liver slices | 0.005 - 10 mmol/L | Negative | (Adams et al., 1998b) |
| | | | Sex-linked recessive lethal mutation | <i>D. melanogaster</i> | 1000 mg/kg of diet | Negative | (Woodruff et al., 1985) |
| | | | Sex-linked recessive lethal mutation | <i>D. melanogaster</i> | 100 mg/kg by injection | Positive | (Woodruff et al., 1985) |
| | | | Sex-linked recessive lethal mutation | <i>D. melanogaster</i> | Up to 6500 mg/kg by injection | Negative | (Rodríguez-Arnaiz et al., 1989) |
| | | | Chromosomal loss | <i>D. melanogaster</i> | Oral or injected dose of 3750–5000 mg/kg of diet. Mated with repair-proficient females | Negative | (Rodríguez-Arnaiz et al., 1992) |
| | | | Chromosomal loss | <i>D. melanogaster</i> | Oral or injected dose of 3750–5000 mg/kg of diet. Mated with repair-deficient females | Positive | (Rodríguez-Arnaiz et al., 1992) |
| | | | Reciprocal trans- location | <i>D. melanogaster</i> | 100 mg/kg by injection | Negative | (Woodruff et al., 1985) |
| | | | Sister chromatid exchange | Mouse bone-marrow cells | 50 - 200 mg/kg bw by | Negative | (NTP, 1990a) |

Table 2.1: Summary of Genotoxicity Data of Furfuryl Derivatives Evaluated by the JECFA (JECFA, 2001b)

| FL-no JECFA-no | EU Register name JECFA name | Structural formula | End-point | Test system | Concentration | Results | Reference |
|-------------------|---|---|-------------------------------|--|---|-------------------------|--------------------------------|
| Furfural (cont.) |  | | Spermhead abnormalities | Mice | injection 4000 mg/kg of diet daily for 5 weeks | Negative | (Subramanyam et al., 1989) |
| | | | Somatic chromo-somal mutation | Swiss albino mouse bone- marrow cells | 1000 - 2000 mg/kg of diet 4000 mg/kg bw for 5 days | Negative Positive | (Subramanyam et al., 1989) |
| | | | Sister chromatid exchange | Adult human lymphocytes | 9454 mg/m ³ in occupational atmosphere | Negative | (Gomez-Arroyo and Souza, 1985) |
| | | | Chromosomal aberration | Adult human lymphocytes | 9454 mg/m ³ in occupational atmosphere | Negative | (Gomez-Arroyo and Souza, 1985) |
| | | | Unscheduled DNA synthesis | B6C3F1 mice | 50 - 320 mg/kg bw orally | Negative | (Edwards, 1999) |
| | | | Unscheduled DNA synthesis | Fischer 344 rats | 5 - 50 mg/kg bw orally | Negative | (Phillips et al., 1997) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA1537, TA100, TA1535 | 288 µg/plate | Negative ^{a,b} | (Florin et al., 1980) |
| 13.001 745 | 5-Methylfurfural |  | Reverse mutation | <i>S. typhimurium</i> TA98, TA100, TA102 | 96,100 µg/plate | Negative ^{a,b} | (Aeschbacher et al., 1989) |
| | | | Reverse mutation | <i>S. typhimurium</i> TA98, TA100 | 79 - 316 µg/plate | Negative ^{a,b} | (Shinohara et al., 1986) |
| | | | DNA repair | <i>B. subtilis</i> H17 (rec+) and M45 (rec-) | 0.55 - 5500 µg/disk | Positive ^{a,b} | (Shinohara et al., 1986) |
| | | | Sister chromatid exchange | Chinese hamster ovary cells | 2200 - 4070 µg/ml | Positive ^{a,b} | (Stich et al., 1981b) |
| | | | | | | | |

a Without metabolic activation from a 9000 g supernatant of rat liver.

b With metabolic activation.

C Concentration added to culture.

Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2

TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Concentration | Result | Reference | Comments |
|--|---------------------------|---|--------------------------------------|--|--|----------|
| Main group I – Non-sulphur-containing Furan Derivatives | | | | | | |
| (Furfuryl alcohol [13.019]) | Ames test | <i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537 | 294 µg/plate | Negative ¹ | (Florin et al., 1980) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100, TA1535 and TA1537 | 10000 µg/plate | Negative ¹ | (Mortelmans et al., 1986) (NTP, 1999a) | |
| | Ames test | <i>S. typhimurium</i> TA100 | 2500 - 12500 µg/ml | Negative ¹ | (Stich et al., 1981a) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100 and TA102 | 198000 µg/plate | Negative ¹ | (Aeschbacher et al., 1989) | |
| | Ames test | <i>S. typhimurium</i> TA98 and TA100 | 81 - 323 µg/plate | Negative ¹ | (Shinohara et al., 1986) | |
| | Modified Ames test | <i>S. typhimurium</i> TA1535, TA100 and TA1537 | 200000 µg/ml | Positive ¹ | (McGregor et al., 1981) | |
| | Rec assay | <i>B. subtilis</i> | 2000 - 20000 µg/disk | Positive ¹ | (Shinohara et al., 1986) | |
| | Sister chromatid exchange | CHO cells | 245 µg/ml | Positive ¹ | (Stich et al., 1981a) | |
| | Sister chromatid exchange | CHO cells | 500 µg/ml | Positive/Weakly positive ² Negative ³ | (NTP, 1999a) | |
| | Sister chromatid exchange | Human Lymphocytes | Up to 196 µg/ml | Negative | (Jansson et al., 1986) | |
| | Sister chromatid exchange | Human Lymphocytes | Up to 970 µg/ml | Negative | (Gomez-Arroyo and Souza, 1985) | |
| | Chromosomal aberration | CHO cells | 2000 µg/ml | Positive | (Stich et al., 1981a) | |
| | Chromosomal aberration | CHO cells | 1600 µg/ml | Negative ¹ | (NTP, 1999a) | |
| | SHE test | Syrian hamster embryo cells | NR | Negative ³ | (Kerckaert et al., 1996) | |
| | Gene Conversion Assay | <i>S. cerevisiae</i> strain D7 | 13500 - 16000 µg/ml | Positive ² | (Stich et al., 1981b) | |
| | Mammalian cell assay | Mouse embryo fibroblast cells (T1) | 10 µg/ml | Negative ² | (Kowalski et al., 2001) | |
| | p53 – induction assay | Mouse embryo fibroblast cells (NCTC 929) | 50 µg/ml | Negative ² | (Duerksen-Hughes et al., 1999) | |
| (Furfuryl acetate [13.128]) | Ames test | <i>S. typhimurium</i> TA1535, TA98 and TA100 | 33 - 666 µg/plate | Positive ² | (Mortelmans et al., 1986) | |
| (Furfural [13.018]) | Ames test | <i>S. typhimurium</i> TA1535, TA100, TA1537, TA1538, TA98 | 0.1 - 1000 µg/ml | Negative ¹ | (McMahon et al., 1979) | |
| | Ames test | <i>S. typhimurium</i> TA100, TA98 and TA1535 | Up to 3460 µg/plate 5766 µg/plate | Negative ¹ Positive ² (weak) | (Loquet et al., 1981) | |
| | Ames test | <i>S. typhimurium</i> TA100, TA98 and TA102 | Up to 115320 µg/plate | Negative ¹ | (Aeschbacher et al., 1989) | |
| | Ames test | <i>S. typhimurium</i> TA100 and TA98 | 15 - 63 µg/plate | Negative ¹ | (Shinohara et al., 1986) | |
| | Ames test | <i>S. typhimurium</i> TA104 | 5 - 500 µg/plate | Positive ³ | (Shane et al., 1988) | |
| | Ames test | <i>S. typhimurium</i> TA100 and TA102 | 5 - 500 µg/plate | Negative ³ | (Shane et al., 1988) | |
| | Ames test | <i>S. typhimurium</i> TA104 and TA102 | 96 µg/plate | Negative | (Marnett et al., 1985a) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100 and TA1535 | Up to 6667 µg/plate | Negative ¹ | (Mortelmans et al., 1986) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100 | Up to 1000 µg | Negative ² | (Osawa and Namiki, 1982) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 | 33 - 6666 µg/plate | Negative ¹ TA100 Equivocal ² | (NTP, 1990a) | |
| | | | | | | |

TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Concentration | Result | Reference | Comments |
|---|---------------------------|--|-----------------------------|------------------------|--------------------------------|---|
| 5-Hydroxymethyl-furfuraldehyde [13.139] | Ames test | <i>S. typhimurium</i> TA100 | 8000 µg/plate | Positive ¹ | (Zdzienicka et al., 1978) | |
| | Ames test | <i>S. typhimurium</i> TA98 | 8000 µg/plate | Negative ¹ | (Zdzienicka et al., 1978) | |
| | Ames test | <i>S. typhimurium</i> TA100, TA102 | 100 - 10000 µg/plate | Negative ² | (Dillon et al., 1998) | |
| | Ames test | <i>S. typhimurium</i> TA104 | 100 - 10000 µg/plate | Equivocal ² | (Dillon et al., 1998) | |
| | Ames test | <i>S. typhimurium</i> TA102, TA104 | 100 - 10000 µg/plate | Negative ³ | (Dillon et al., 1998) | |
| | Ames test | <i>S. typhimurium</i> TA100 | 100 - 10000 µg/plate | Equivocal ³ | (Dillon et al., 1998) | |
| | Modified Ames test | <i>S. typhimurium</i> TA100 | 426 µg/plate | Negative | (Kim et al., 1987b) | |
| | Modified Ames test | <i>S. typhimurium</i> TA100, TA1535 and TA1537 | 200000 µg/ml | Negative | (McGregor et al., 1981) | |
| | Modified Ames test | <i>E. coli</i> WP2 and WP2 uvrA | 0.1 - 1000 µg/ml | Negative ¹ | (McMahon et al., 1979) | |
| | SOS induction | <i>S. typhimurium</i> TA1535/ pSK1002 | 1932 µg/ml | Negative ¹ | (Nakamura et al., 1987) | |
| | Rec-assay | <i>B. subtilis</i> H17 & M45 | Up to 1000 µg | Negative | (Osawa and Namiki, 1982) | |
| | Rec-assay | <i>B. subtilis</i> H17 & M45 | 0.6 ml | Negative ¹ | (Matsui et al., 1989) | |
| | Rec-assay | <i>B. subtilis</i> strains H17 & M45 | 1700 - 17000 µg/disk | Positive ¹ | (Shinohara et al., 1986) | |
| | Forward mutation assay | L5178Y tk+/- Mouse Lymphoma Cells | 25 - 100 µg/ml | Negative ² | (McGregor et al., 1988b) | |
| | | | 200 µg/ml | Positive ² | | |
| | Sister chromatid exchange | CHO cells | 2500 - 4000 µg/ml | Positive ¹ | (Stich et al., 1981a) | |
| | Sister chromatid exchange | CHO cells | Up to 1170 µg/ml | Positive ¹ | (NTP, 1990a) | |
| | Sister chromatid exchange | Human Lymphocytes | Up to 0.035 mM ⁴ | Negative ¹ | (Gomez-Arroyo and Souza, 1985) | |
| | | | 0.07 - 0.14 Mm ⁴ | Positive ¹ | | |
| | Chromosomal aberration | CHO cells | 500 µg/ml | Negative | (Nishi et al., 1989) | |
| | | | 1000 - 2000 µg/ml | Positive | | |
| | Chromosomal aberration | CHO cells | Up to 40 mM (3,840 mg) | Positive ¹ | (Stich et al., 1981a) | |
| | Chromosomal aberration | CHO cells | 3000 µg/ml | Positive | (Stich et al., 1981b) | |
| | Chromosomal aberration | CHO cells | 375 µg/ml ² | Positive | (Gudi and Schadly, 1996) | |
| | | | 750 µg/ml ³ | | | |
| | Chromosomal aberration | CHO cells | Up to 1,230 µg/ml | Positive ¹ | (NTP, 1990a) | |
| | Unscheduled DNA Synthesis | Human liver slices | 0.005 - 10 mM | Negative | (Adams et al., 1998b) | |
| | DNA-protein cross-links | EBV- human Burkitt's lymphoma cells | 25 mM | Positive ⁵ | (Costa et al., 1997) | |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 0.2 - 1 µmol/plate | Negative | (Surh et al., 1994) | The study is considered valid. Purity 99 %. |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 0.2 - 2.0 µg/plate | Positive ¹ | (Omura et al., 1983) | Posititive dose related respons in TA100 only, most potent without S9. Purity and other experimental details not reported. The validity of the study cannot be evaluated. |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 0.17 - 0.66 µmol/plate | Positive ¹ | (Shinohara et al., 1986) | Positive results only obtained in TA100 with S9. Reverse dose-respons relationship. Experimental details are lacking. |
| | Ames test | <i>S. typhimurium</i> TA104 | 0.1 - 0.8 mM | Negative ² | (Lee et al., 1995b) | Positive result was obtained |

TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Concentration | Result | Reference | Comments |
|------------------------|------------------------|--|---------------------------------------|------------------------------|------------------------------|--|
| | | | | Positive | | by inclusion of PAPS and the rat liver cytosol in the assay. The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 1 - 50 µl/plate ³ | Negative ¹ | (Aeschbacher et al., 1981) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA100 | 4.44 µM/plate | Negative ² | (Kim et al., 1987b) | Single dose only. |
| | Ames test | <i>S. typhimurium</i> TA98; TA100; TA1535; TA1537 | 3 µmol/plate | Negative ¹ | (Florin et al., 1980) | Spot test. The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA100 | 10 µg/plate | Negative ² | (Majeska and McGregor, 1992) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA97, TA98, TA102, TA1535 | 100 - 10,000 µg/plate | Negative ¹ | (NTP, 2010c) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA100 | 100 - 10,000 µg/plate | Weakly positive ² | (NTP, 2010c) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA100 and TA98 | 1,500 - 10,000 µg/plate | Negative ¹ | (NTP, 2010c) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 | at 0.5 µg/mL up to 5000 µg/mL | Negative ¹ | (Severin et al., 2010) | For discussion and interpretation see text. |
| | Reverse mutation assay | <i>E. coli</i> WP2 uvrA/pKM101 | 1,500 - 10,000 µg/plate | Negative ¹ | (NTP, 2010c) | The study is considered valid. |
| | Micronucleus assay | HepG2 cells | 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM | Negative ¹⁵ | (Severin et al., 2010) | For discussion and interpretation see text. |
| | SCE induction | V79-hCYP2E1-hSULT1A1 cells | 19.8 - 3808 µM | Positive | (Glatt et al., 2005) | For discussion and interpretation see text. |
| | SCE induction | V79-Mz cells | 238 - 3808 µM, | Positive ¹⁶ | (Glatt et al., 2005) | For discussion and interpretation see text. |
| | <i>Umu</i> assay | <i>S. typhimurium</i> TA1535 | 20 mM | Positive ⁹ | (Janzowski et al., 2000) | Positive results were only obtained at high concentrations resulting in reduced cell viability and growth. The study is considered valid but interpretation of data is questionable. |
| | Rec assay | <i>B. subtilis</i> H 17 rec+; M 45 rec- | 0.25 - 12.5 mg/disk | Positive ¹ | (Shinohara et al., 1986) | Experimental details are lacking. The validity of the study cannot be evaluated. |
| | Chromosomal aberration | Chinese hamster V79 cells | Up to 2000 µg/ml | Positive ¹⁰ | (Nishi et al., 1989) | Weak positive response were only obtained at high concentrations. The study is considered valid. |
| | Comet assay | V79, Caco-2, primary human colon cells and primary rat hepatocytes | Up to 80 mM | Negative ² | (Janzowski et al., 2000) | The study is considered valid but interpretation of data is questionable. |
| | Comet assay | HepG2 cells | 0, 5.35, 7.87, 11.57, 17, | Positive ^{14,15} | (Severin et al., 2010) | For discussion and |

TABLE 2.2: GENOTOXICITY (IN VITRO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Concentration | Result | Reference | Comments |
|-----------------------------|---------------------------|---|---------------------------------------|---------------------------|-----------------------------|---|
| | | | 25, 36.6 mM | | | interpretation see text. |
| | Comet assay | Human Caco-2 cells | 3,153 - 12,611 µg/mL (25 - 100 mM) | Positive ¹² | (Durling et al., 2009) | For discussion and interpretation see text. |
| | Comet assay | Human HEK293 cells | 3,153 - 12,611 µg/mL (25 - 100 mM) | Positive ¹² | (Durling et al., 2009) | For discussion and interpretation see text. |
| | Comet assay | Mouse lymphoma L5178Y cells | 3,153 - 12,611 µg/mL (25 - 100 mM) | Positive ¹² | (Durling et al., 2009) | For discussion and interpretation see text. |
| | Comet assay | Chinese hamster V-79 cells | 315 - 12,611 µg/mL (2.5 - 100 mM) | Positive ¹³ | (Durling et al., 2009) | For discussion and interpretation see text. |
| | Comet assay | Chinese hamster V-79-hP-PST cells | 315 - 12,611 µg/mL (2.5 - 100 mM) | Positive ¹³ | (Durling et al., 2009) | For discussion and interpretation see text. |
| | HPRT assay | V79 cells | Up to 140 mM | Positive ^{1,11} | (Janzowski et al., 2000) | Positive response were only obtained at high concentrations resulting in reduced cell viability and growth. The study is considered valid but interpretation of data is questionable. |
| (5-Methylfurfural [13.001]) | HPRT and tk assay | TK6 human lymphoblast cells | 20 - 75 µg/ml | Negative | (Surh and Tannenbaum, 1994) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA1537, TA100 and TA1535 | 288 µg/plate | Negative ¹ | (Florin et al., 1980) | |
| | Ames test | <i>S. typhimurium</i> TA98, TA100 and TA102 | 96100 µg/plate | Negative ¹ | (Aeschbacher et al., 1989) | |
| | Ames test | <i>S. typhimurium</i> TA98 and TA100 | 79 - 316 µg/plate | Negative ¹ | (Shinohara et al., 1986) | |
| | Rec-assay | <i>B. subtilis</i> strains H17 & M45 | 0.55 - 5500 µg/disk | Positive ¹ | (Shinohara et al., 1986) | |
| 2-Furoic acid [13.136] | Sister chromatid exchange | CHO cells | 2200 - 4070 µg/ml | Positive ¹ | (Stich et al., 1981a) | |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 25 - 100 µg/plate | Negative ² | (Ichikawa et al., 1986b) | The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA100 | | Negative | (Soska et al., 1981) | Dose not reported. The validity of the study can not be evaluated. |
| | Ames test | <i>S. typhimurium</i> TA100 | 1000 µg/plate | Negative | (Kitamura et al., 1978) | The study is considered valid. |
| | DNA repair test | <i>E. coli</i> WP21 WP2 uvrA; WP67; WP100; CM 561; CM 571; CM 611 | 1000 µg/disk | Negative | (Soska et al., 1981) | The study is considered valid. |
| (Methyl-2-furoate [13.002]) | Unscheduled DNA synthesis | Primary rat hepatocytes | 1000 µg/ml | Negative ^{10,17} | (Aaron et al., 1989) | Study performed in accordance with GLP. The study is considered valid. |
| | Ames test | <i>S. typhimurium</i> TA98; TA100 | 100 µg/plate | Negative ¹⁰ | (Ichikawa et al., 1986b) | |

NR=Not Reported.

¹With and without S9 metabolic activation.

²Without S9 metabolic activation.

³With S9 metabolic activation.

⁴Concentration added to the culture.

⁵Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death).

⁶ TA98 with S9 metabolic activation; TA100 without S9 metabolic activation.

⁷ 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan without the presence of nitrite treatment.

⁸ 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan treated with nitrite.

⁹ At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.

¹⁰ Metabolic activation not reported.

¹¹ Effects occurred at concentrations inhibiting cellular growth.

¹² Positive only at the highest concentration tested with significant decrease in cell viability.

¹³ Positive at high concentration with significantly reduced cell viability.

¹⁴ Cytotoxic at the two highest doses.

¹⁵ 20 hours of exposure.

¹⁶ Weakly positive but statistically significant at each concentration.

¹⁷ Dose levels above 300 microgram/ml were cytotoxic.

Substances listed in brackets are the JECFA evaluated supporting substances in FGE.13Rev2

TABLE 2.3: GENOTOXICITY (IN VIVO) EVALUATED BY EFSA IN FGE.13REV2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Route | Dose | Result | Reference | Comments |
|-----------------------------|----------------------------------|--|--------------------------------------|---|-----------------------|---------------------------------|----------|
| (Furfuryl alcohol [13.019]) | Sex-linked recessive lethal test | <i>D. melanogaster</i> | Injection | Up to 6500 ppm | Negative | (Rodríguez-Arnaiz et al., 1989) | |
| | Sister chromatid exchange | Adult Human Lymphocytes | Inhalation (occupational atmosphere) | 32300 mg/m ³ | Negative | (Gomez-Arroyo and Souza, 1985) | |
| | Chromosomal aberration assay | Adult Human Lymphocytes | Inhalation (occupational atmosphere) | 32300 mg/m ³ | Negative | (Gomez-Arroyo and Souza, 1985) | |
| | Chromosomal aberration assay | Mouse bone marrow cells | Drinking water | 0.5 mg/kg 1 - 2 mg/kg | Negative Positive | (Sujatha and Subramanyam, 1994) | |
| | Sister chromatid exchange | Mouse bone marrow cells | IP injection | 300 mg/kg | Negative | (NTP, 1999a) | |
| | Chromosomal aberration assay | Mouse bone marrow cells | IP injection | 300 mg/kg | Negative | (NTP, 1999a) | |
| | Micronucleus assay | Mouse bone marrow cells | IP injection | 250 mg/kg | Negative | (NTP, 1999a) | |
| | Mouse bioassay | Tg-AC transgenic mice | Dermal exposure | 1.5 mg; 5 days/week for 20 weeks | Negative | (Spalding et al., 2000) | |
| (Furfural [13.018]) | Sex-linked recessive lethal test | <i>D. melanogaster</i> | Diet | 1000 ppm | Negative | (Woodruff et al., 1985) | |
| | Sex-linked recessive lethal test | <i>D. melanogaster</i> | Injection | 100 ppm | Positive | (Woodruff et al., 1985) | |
| | Sex-linked recessive lethal test | <i>D. melanogaster</i> | Injection | Up to 6500 ppm | Negative | (Rodríguez-Arnaiz et al., 1989) | |
| | Chromosome Loss | <i>D. melanogaster</i> | Oral or injected | 3750 - 5000 ppm. Mated with repair-proficient females | Negative | (Rodríguez-Arnaiz et al., 1992) | |
| | Chromosome Loss | <i>D. melanogaster</i> | Oral or injected | 3750 - 5000 ppm. Mated with repair-deficient females | Positive | (Rodríguez-Arnaiz et al., 1992) | |
| | Reciprocal translocations | <i>D. melanogaster</i> | Injection | 100 ppm | Negative | (Woodruff et al., 1985) | |
| | Nondisjunction assay | <i>D. melanogaster</i> (females) | Inhalation | 1.5 % | Negative ¹ | (Muñoz and Barnett, 1999) | |
| | Sister chromatid exchange | Mouse bone marrow cells | Injection | 50 - 200 mg/kg | Negative | (NTP, 1990a) | |
| | Sperm head abnormalities | Mouse | Oral | 4000 ppm daily for 5 weeks | Negative | (Subramanyam et al., 1989) | |
| | Somatic chromosome mutations | Swiss albino mouse (bone marrow cells) | | 1000 - 2000 ppm 4000 ppm for 5 days | Negative Positive | (Subramanyam et al., 1989) | |
| | Sister chromatid exchange | Adult Human Lymphocytes | Inhalation (occupational atmosphere) | 9454 mg/m ³ | Negative | (Gomez-Arroyo and Souza, 1985) | |
| | Chromosomal aberration assay | Adult Human Lymphocytes | Inhalation (occupational atmosphere) | 9454 mg/m ³ | Negative | (Gomez-Arroyo and Souza, 1985) | |

TABLE 2.3: GENOTOXICITY (*IN VIVO*) EVALUATED BY EFSA IN FGE.13Rev2 (EFSA, 2011H)

| Chemical Name [FL-no:] | Test system | Test Object | Route | Dose | Result | Reference | Comments |
|----------------------------------|--|---|-------|--------------------------------------|----------|-------------------------|---|
| | Unscheduled DNA synthesis | Mouse | Oral | 50 - 320 mg/kg | Negative | (Edwards, 1999) | |
| | Unscheduled DNA synthesis | F344 Rat | Oral | 5 - 50 mg/kg | Negative | (Phillips et al., 1997) | |
| | Gene mutation in the <i>λlacZ</i> - <i>gene</i> in liver | Transgenic mouse CD2F ₁ (BALB/c x DBA/2) | Oral | 75 - 300 mg/kg | Negative | (CIVO-TNO, 2003) | |
| 5-Hydroxymethylfurfural [13.139] | Micronucleus assay | Mouse peripheral blood cells | | 47, 94, 188, 375 or 750 mg/kg bw/day | Negative | (NTP, 2010c) | 3-months micronucleus assay. Limited validity in absence of bone-marrow toxicity. |

¹ Exposure to 1 % solutions did not affect the flies' behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of nondisjunction.

Table 2.4: Genotoxicity on Furfural, SCF Opinion December 2002 (SCF, 2003a)

| Substance | End-point | Test object | Concentration | Result | Reference |
|------------------------|---|---|---|--------------------------------------|--|
| <i>In vitro</i> | | | | | |
| Furfural [13.018] | Reverse mutation | <i>S. typhimurium</i> TA100, TA98, TA1535 | 0.05 - 60 µmol/plate | Weakly positive (TA100) ^b | (Loquet et al., 1981) |
| | | <i>S. typhimurium</i> TA100, TA98, TA102 | ≤ 1.2 mmol/plate | Negative ^a | (Aeschbacher et al., 1989) |
| | | <i>S. typhimurium</i> TA100, TA98 | 0.165 - 0.660 µmol/plate | Negative ^a | (Shinohara et al., 1986) |
| | | <i>S. typhimurium</i> TA102, TA104 | 5 - 500 µg/plate | Positive (TA104) | (Shane et al., 1988) |
| | | <i>S. typhimurium</i> TA98, TA100, TA1535, TA1537 | 33.3 - 6666 µmol/plate | Negative ^a | (Mortelmans et al., 1986) |
| | | <i>S. typhimurium</i> TA98, TA100 | 1 - 15 µL/plate | Positive ^a (TA100) | (Zdzienicka et al., 1978) |
| | | <i>S. typhimurium</i> TA98, TA100 | 7 µL/plate | Negative ^a | (Sasaki and Endo, 1978) |
| | | <i>S. typhimurium</i> TA100 | 4.44 µmol/plate | Negative ^a | (Osawa and Namiki, 1982) |
| | | <i>S. typhimurium</i> TA98, TA100, TA104, <i>E. coli</i> WP2uvrA/PKM101 | 20 µL/plate | Negative ^a | (McMahon et al., 1979) |
| | | <i>S. typhimurium</i> TA104 | 1 µmol (max. non-toxic dose) | Negative ^b | (Marnett et al., 1985a) |
| | Umu gene expression | <i>S. typhimurium</i> TA1535/pSK/1002 | 1932 µg/mL | Negative ^a | (Nakamura et al., 1987) |
| | Rec assay | <i>B. subtilis</i> H17, M45 | 1.7 - 17 mg/disk | Positive ^a | (Shinohara et al., 1986) |
| | | <i>B. subtilis</i> H17, M45 | 1 mg/disk | Negative ^a | (Matsui et al., 1989) |
| | Forward mutation | L5178Ytk+/- mouse lymphoma cells | 25 - 800 µg/mL | Positive ^b | (McGregor et al., 1988b) |
| | Chromosomal aberration | Chinese hamster ovary cells | 10-40 mM | Positive ^a | (Stich et al., 1981a; Stich et al., 1981b) |
| | | Chinese hamster ovary cells | 200 - 1230 µg/mL | Positive ^a | (Galloway et al., 1985) |
| | | Chinese hamster ovary cells | 1.5 - 5000 µg/mL | Positive ^a | (Gudi and Schadly, 1996) |
| | | Chinese hamster V79 cells | 500 - 2000 µg/mL | Positive ^a | (Nishi et al., 1989) |
| | | Chinese hamster ovary cells | 11.7 - 3890 µg/mL | Positive ^a | (Galloway et al., 1985) |
| | Sister chromatid exchange | Human peripheral lymphocytes | 3.5 - 14x10 ⁻⁵ M | Positive ^b | (Gomez-Arroyo and Souza, 1985) |
| | | Human liver slices | 0.14 mmol/L | Negative | (Lake, 1998) |
| | Unscheduled DNA synthesis | Human liver slices | 0-25 mmol/L | Negative | (Lake, 1998) |
| <i>In vivo</i> | | | | | |
| Furfural [13.018] | Sex-linked recessive lethal mutation | <i>D. melanogaster</i> | 1000 ppm, in diet | Negative | (Woodruff et al., 1985) |
| | | <i>D. melanogaster</i> | 100 ppm, by injection | Positive | (Woodruff et al., 1985) |
| | Wing spot test | <i>D. melanogaster</i> | 3750 - 7500 ppm by aerial exposure | Positive | (Rodríguez-Arnaiz et al., 1989) |
| | Sex-chromosome loss | <i>D. melanogaster</i> | 3750 - 5000 ppm, in diet and by injection | Positive on injection | (Rodríguez-Arnaiz et al., 1989; Rodríguez-Arnaiz et al., 1992) |
| | | <i>D. melanogaster</i> | 1000 ppm, in diet | Negative | (Woodruff et al., 1985) |
| | Reciprocal translocation | <i>D. melanogaster</i> | 1000 ppm, in diet | Negative | (Woodruff et al., 1985) |
| | Sister chromatid exchange/ chromosomal aberration | B6C3F1 mouse bone marrow cells | 50 - 200 mg/kg bw, once i.p. | Negative | (NTP, 1990a) |
| | Somatic chromosomal aberration | Swiss albino mouse bone marrow cells | 4000 ppm for 5 days, in diet | Negative | (Subramanyam et al., 1989)+ |
| | Sperm head abnormalities | Swiss albino mouse | 4000 ppm for 5 weeks, in diet | Negative | (Subramanyam et al., 1989)+ |
| | Unscheduled DNA synthesis | Fischer 344 rat hepatocytes | 5.0, 16.7 or 50 mg/kg bw, orally | Negative | (Phillips et al., 1997) |
| | | B6C3F1 mouse hepatocytes | 50, 175 or 320 mg/kg bw, orally | Negative | (Edwards, 1999) |

^a With and without metabolic activation.

^b Without metabolic activation.

+ Abstract only; no details available.

TABLE 3: SUMMARY OF SAFETY EVALUATIONS

Table 3.1: Summary of Safety Evaluation of 14 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b)















| FL-no JECFA-no | EU Register name | Structural formula | EU MSDI 1) US MSDI (µg/capita/day) | Class 2) Evaluation procedure path 3) | Outcome on the named compound [4) or 5)] | EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity) | EFSA conclusion on the material of commerce |
|-------------------|----------------------|---|--|---|--|---|--|
| 13.001 745 | 5-Methylfurfural |  | 180 25 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.002 746 | Methyl 2-furoate |  | 30 37 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.003 747 | Propyl 2-furoate |  | 0.061 0.1 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.018 450 | Furfural |  | 440 460 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.019 451 | Furfuryl alcohol |  | 180 24 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. Separate EFSA opinion available. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.057 743 | Furfuryl isovalerate |  | 0.024 1 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.062 740 | Furfuryl propionate |  | 1.7 5 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.068 741 | Furfuryl valerate |  | 0.24 14 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.128 739 | Furfuryl acetate |  | 16 21 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.005 749 | Hexyl 2-furoate |  | 0.061 0.1 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach. | No safety concern at the estimated level of intake based on the MSDI approach. |

Table 3.1: Summary of Safety Evaluation of 14 JECFA-Evaluated Furfuryl Derivatives (JECFA, 2001b)

| FL-no JECFA-no | EU Register name | Structural formula | EU MSDI 1) US MSDI ($\mu\text{g/capita/day}$) | Class 2) Evaluation procedure path 3) | Outcome on the named compound [4) or 5)] | EFSA conclusion on the named compound (Procedure steps, intake estimates, NOAEL, genotoxicity) | EFSA conclusion on the material of commerce |
|-------------------|----------------------------|---|---|---|--|---|---|
| 13.025 748 | Pentyl 2-furoate |  | 0.36 0.1 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.038 752 | 2-Phenyl-3-carbethoxyfuran |  | 0.012 2 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.067 742 | Furfuryl octanoate |  | 0.012 6 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach | No safety concern at the estimated level of intake based on the MSDI approach. |
| 13.073 750 | Octyl 2-furoate |  | 2.2 0.1 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | No safety concern at the estimated level of intake based on the MSDI approach | No safety concern at the estimated level of intake based on the MSDI approach. |

1) EU MSDI: Amount added to food as flavour in (kg / year) $\times 10E9 / (0.1 \times \text{population in Europe} (= 375 \times 10E6) \times 0.6 \times 365) = \mu\text{g/capita/day}$.

2) Thresholds of concern: Class I = 1800 $\mu\text{g/person/day}$, Class II = 540 $\mu\text{g/person/day}$, Class III = 90 $\mu\text{g/person/day}$.











3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

4) No safety concern based on intake calculated by the MSDI approach of the named compound.

5) Data must be available on the substance or closely related substances to perform a safety evaluation.

ND: not determined.

Table 3.2: Summary of Safety Evaluation Applying the Procedure for 10 Furfuryl Derivatives of FGE.13Rev2 (REF:6915)

| FL-no | EU Register name | Structural formula | MSDI 1) (µg/capita/day) | Class 2) Evaluation procedure path 3) | Outcome on the named compound [4) or 5] | Outcome on the material of commerce [6), 7), or 8)] | Evaluation remarks |
|---------------|-------------------------------|---|----------------------------|---|---|--|-----------------------|
| 13.122 | Ethyl 2-furoate |  | 0.39 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.130 759 | Furfuryl butyrate |  | 0.24 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.136 | 2-Furoic acid |  | 0.013 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.139 | 5-Hydroxymethylfurfuraldehyde |  | 0.39 | Class II B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.011 | Ethyl furfuracrylate |  | 0.12 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.102 | Butyl 2-furoate |  | 0.12 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.127 | Furfuryl 2-methylbutyrate |  | 0.73 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.129 | Furfuryl but-2-enoate |  | 0.11 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.132 | Furfuryl hexanoate |  | 0.58 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |
| 13.133 | Furfuryl isobutyrate |  | 0.89 | Class III B3: Intake below threshold, B4: Adequate NOAEL exists | 4) | 6) | |

1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita/day.

2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day.

3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.

4) No safety concern based on intake calculated by the MSDI approach of the named compound.

5) Data must be available on the substance or closely related substances to perform a safety evaluation.

6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach).

7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism.

8) No conclusion can be drawn due to lack of information on the purity of the material of commerce.

REFERENCES

- Aaron CS, Harbach PR, Wiser SK, Grzegorzczak CR and Smith AL, 1989. The *in vitro* unscheduled DNA synthesis (UDS) assay in rat primary hepatocytes: Evaluation of 2-furoic acid and 7 drug candidates. *Mutat. Res.* 223(2), 163-169.
- Adams TB, Lake BG, Beamad JA, Price RJ, Ford RA and Goodman JJ, 1998b. An investigation of the effect of furfural on the unscheduled DNA synthesis in cultured human liver slices. *Toxicologist* 42(1-S), 79.
- Aeschbacher HU, Chappus C, Manganel M and Aeschbacher R, 1981. Investigation of maillard products in bacterial mutagenicity test systems. *Prog. Food Nutr. Sci.* 5, 279-294.
- Aeschbacher HU, Wolleb U, Loliger J, Spadone JC and Liardon R, 1989. Contribution of coffee aroma constituents to the mutagenicity of coffee. *Food Chem. Toxicol.* 27(4), 227-232.
- Archer MC, Bruce WR, Chan CC, Corpet DE, Medline A, Roncucci L, Stamp D and Zhang X-M, 1992. Aberrant crypt foci and microadenoma as markers for colon cancer. *Environ. Health Perspect.* 98(0), 195-197.
- Bruce WR, Archer MC, Corpet DE, Medline A, Minkin S, Stamp D, Yin Y and Zhang XM, 1993. Diet, aberrant crypt foci and colorectal cancer. *Mutat. Res.* 290, 111-118.
- CIVO-TNO, 2003. *In vivo* gene mutation by use of lambdaZ-transgenic mice with furfural. Steenwinkel, M.-J.S.T. Project no. 01044074. 1 May 2003. Unpublished report submitted to EFSA.
- Costa M, Zhitkovich A, Harris M, Paustenbach D and Gargas M, 1997. DNA-protein cross-links produced by various chemicals in cultured human lymphoma cells. *J. Toxicol. Environ. Health* 50(5), 433-449.
- Cramer GM, Ford RA and Hall RL, 1978. Estimation of toxic hazard - a decision tree approach. *Food Cosmet. Toxicol.* 16(3), 255-276.
- Dahlberg J, 2004. "Genotoxiciteten av HMF: s metabolit SMF studerad med det flödescytometerbaserade mikrokärntestet *in vivo*", Examination work supervised by Abramsson-Zetterberg L, University of Uppsala, Uppsala, 34 pp. (as cited by Glatt and Sommer 2006).
- Dillon D, Combes R and Zeiger E, 1998. The effectiveness of *Salmonella* strains TA100, TA102 and TA104 for detecting mutagenicity of some aldehydes and peroxides. *Mutagenesis* 13(1), 19-26.
- Duerksen-Hughes PJ, Yang J and Ozcan O, 1999. p53 induction as a genotoxic test for twenty-five chemicals undergoing *in vivo* carcinogenicity testing. *Environ. Health Perspect.* 107(10), 805-812.
- Durling LJK, Busk L and Hellman BE, 2009. Evaluation of the DNA damaging effect of the heat-induced food toxicant 5-hydroxymethylfurfural (HMF) in various cell lines with different activities of sulfotransferases. *Food Chem Toxicol.* 47, 880-884.
- EC, 1996a. Regulation No 2232/96 of the European Parliament and of the Council of 28 October 1996. *Official Journal of the European Communities* 23.11.1996, L 299, 1-4.
- EC, 1999a. Commission Decision 1999/217/EC of 23 February 1999 adopting a register of flavouring substances used in or on foodstuffs. *Official Journal of the European Communities* 27.3.1999, L 84, 1-137.
- EC, 2000a. Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an evaluation programme in application of Regulation (EC) No 2232/96. *Official Journal of the European Communities* 19.7.2000, L 180, 8-16.
- EC, 2009a. Commission Decision 2009/163/EC of 26 February 2009 amending Decision 1999/217/EC as regards the Register of flavouring substances used in or on foodstuffs. *Official Journal of the European Union* 27.2.2009, L 55, 41.

- Edwards A, 1999. Draft report. An *in vivo* unscheduled DNA synthesis assay in the mouse with furfural. Report no. 3389/1/1/99. BIBRA International, Carshalton.
- EFFA, 2000e. Submission from EFFA to The Experts of the Coordination Institute of the SCOOP task 1.1, Danish Veterinary and Food Administration. 2000. Re.: Furfural - foodnoted substance of the EU Register of flavouring substances - FLAVIS 13.018
- EFSA, 2004c. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to furfural and furfural diethylacetal. Question number EFSA-Q-2003-236. Adopted by written procedure on 2 June 2004. The EFSA Journal 67, 1-27.
- EFSA, 2004d. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to Flavouring Group Evaluation 03: Acetals of branched- and straight-chain aliphatic saturated primary alcohols and branched- and straight-chain saturated aldehydes, and an orthoester of formic acid, from chemical groups 1 and 2 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 7 October 2004. EFSA-Q-2003-146.
- EFSA, 2005c. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to Flavouring Group Evaluation 13: Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms from chemical group 14 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 27 April 2005. EFSA-Q-2003-156.
- EFSA, 2008b. Minutes of the 26th Plenary meeting of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food, Held in Parma on 27 - 29 November 2007. Parma, 7 January 2008. [Online]. Available: http://www.efsa.europa.eu/EFSA/Event_Meeting/afc_minutes_26thplen_en.pdf
- EFSA, 2009s. Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in contact with food on a request from the Commission related to Flavouring Group Evaluation 218: alpha,beta-Unsaturated aldehydes and precursors from subgroup 4.2 of FGE.19: Furfural derivatives (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 9 July 2008. EFSA-Q-2008-426.
- EFSA, 2010aj. Opinion of the Scientific Panel on contact Materials, Enzymes, Flavourings and Processing Aids on a request from Commission related to Flavouring Group Evaluation 96 (FGE.96), addendum to FGE. 50, 51, 52, 53, 54, 56, 58, 59, 61, 62, 63, 64, 66, 68, 69, 70, 71, 73, 76, 77, 79, 80, 83, 84, 85, 86 and 87: Consideration of 102 flavouring substances considered by EFSA for which EU production volumes / anticipated production volumes have been submitted on request by DG SANCO (Commission Regulation (EC) No 1565/2000 of 18 July 2000).
- EFSA, 2010ak. Opinion of the Scientific Panel on contact Materials, Enzymes, Flavourings and Processing Aids on a request from Commission related to Flavouring Group Evaluation 218, Revision 1 (FGE.218Rev1): alpha,beta-Unsaturated aldehydes and precursors from subgroup 4.2 of FGE.19: Furfural derivatives (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 30 September 2010. EFSA-Q-2009-01083.
- EFSA, 2011h. Opinion of the Scientific Panel on contact Materials, Enzymes, Flavourings and Processing Aids on a request from the Commission related to Flavouring Group Evaluation 13, Revision 2: Furfuryl and furan derivatives with and without additional side-chain substituents and heteroatoms from chemical group 14 (Commission Regulation (EC) No 1565/2000 of 18 July 2000). Adopted on 6 July 2011. EFSA-Q-2010-01555, EFSA-Q-2011-00041, EFSA-Q-2011-00815, EFSA-Q-2011-00816, EFSA-Q-2011-00859, EFSA-Q-2011-00860, EFSA-Q-2011-00861.
- Florin I, Rutberg L, Curvall M and Enzell CR, 1980. Screening of tobacco smoke constituents for mutagenicity using the Ames' test. Toxicology. 18, 219-232.
- Galloway SM, Bloom AD, Resnick M, Margolin BH, Nakamura F, Archer P and Zeiger E, 1985. Development of a standard protocol for *in vitro* cytogenetic testing with chinese hamster ovary cells: comparison of results for 22 compounds in two laboratories. Environ. Mutag. 7, 1-51.

- Glatt HR and Sommer Y, 2006. Health risks by 5-hydroxymethylfurfural (HMF) and related compounds. In: Acrylamide and Other Health Hazardous Compounds in Heat-treated Foods (K. Skog, J. Alexander, eds.), Woodhead Publishing, Cambridge, 2006, 328-357.
- Glatt H, Schneider H and Liu Y, 2005. V79-hCYP2E1-hSULT1A1, a cell line for the sensitive detection of genotoxic effects induced by carbohydrate pyrolysis products and other food-borne chemicals. *Mutation Research* 580, 41-52.
- Gomez-Arroyo S and Souza VS, 1985. *In vitro* and occupational induction of sister-chromatid exchanges in human lymphocytes with furfuryl alcohol and furfural. *Mutat. Res.* 156, 233-238.
- Gorelick NJ and Mirsalis JC, 1996. A strategy for the application of Transgenic Rodent Mutagenesis Assays. *Environ. Mol. Mutagen.* 28, 434-442.
- Gudi R and Schadly EH, 1996. *In vitro* mammalian cytogenetic test with an independent repeat assay of furfural, final report, with cover letter dated 11/22/1996 (sanitized). Furfural. Microbiological Associates, Inc. EPA Doc 88970000074S, microfiche no. OTS0559061. November 19, 1996. Unpublished report submitted by EFFA to FLAVIS Secretariat.
- Heddle JA, Dean S, Nohmi T, Boerrigter M, Casciano D, Douglas GR, Glickman BW, Gorelick NJ, Mirsalis JC, Martus H-J, Skopek TR, Thybaud V, Tindall KR and Yajima N, 2000. *In vivo* transgenic mutation assays. *Environ. Mol. Mutagen.* 35, 253-259.
- Ichikawa M, Yamamoto K, Tanaka A, Swaminathan S, Hatcher JF, Erturk E and Bryan GT, 1986b. Mutagenicity of 3,4-diphenyl-5-nitrofurans analogs in *Salmonella typhimurium*. *Carcinogenesis* 7(8), 1339-1344.
- Jansson T, Curvall M, Hedin A and Enzell C, 1986. *In vitro* studies of biological effects of cigarette smoke condensate. II. Induction of sister-chromatid in human lymphocytes by weakly acidic, semivolatile constituents. *Mutat. Res.* 169, 129-139.
- Janzowski C, Glaab V, Samimi E, Schlatter J and Eisenbrand G, 2000. 5-Hydroxymethylfurfural: assessment of mutagenicity, DNA-damaging potential and reactivity towards cellular glutathione. *Food Chem. Toxicol.* 38(9), 801-809.
- JECFA, 1992a. 39. Report: Thirty-ninth Meeting of the Joint FAO/WHO Expert Committee on Food Additives. Report: WHO Technical Report Series, no. 828.
- JECFA, 1995. Evaluation of certain food additives and contaminants. Forty-fourth Meeting of the Joint FAO/WHO Expert Committee on Food Additives. 14-23 February 1995. WHO Technical Report Series, no. 859. Geneva.
- JECFA, 1996a. Toxicological evaluation of certain food additives. The forty-fourth meeting of the Joint FAO/WHO Expert Committee on Food Additives and contaminants. WHO Food Additives Series: 35. IPCS, WHO, Geneva.
- JECFA, 1997a. Evaluation of certain food additives and contaminants. Forty-sixth report of the Joint FAO/WHO Expert Committee on Food Additives. Geneva, 6-15 February 1996. WHO Technical Report Series, no. 868. Geneva.
- JECFA, 1999b. Evaluation of certain food additives and contaminants. Forty-ninth report of the Joint FAO/WHO Expert Committee on Food Additives. Rome, 17-26 June 1997. WHO Technical Report Series, no. 884. Geneva.
- JECFA, 2000a. Evaluation of certain food additives. Fifty-first meeting of the Joint FAO/WHO Expert Committee on Food Additives. Geneva, 9-18 June 1998. WHO Technical Report Series, no. 891. Geneva.
- JECFA, 2000d. Compendium of food additive specifications. Addendum 8. Joint FAO/WHO Expert Committee of Food Additives. 55th meeting. Geneva, 6-15 June 2000. FAO Food and Nutrition paper 52 Add. 8.
- JECFA, 2001a. Evaluation of certain food additives and contaminants. Fifty-fifth report of the Joint FAO/WHO Expert Committee on Food Additives. WHO Technical Report Series, no. 901. Geneva, 6-15 June 2000.

- JECFA, 2001b. Safety evaluation of certain food additives and contaminants. Fifty-fifth meeting of the Joint FAO/WHO Expert Committee on Food Additives, WHO Food Additives Series: 46. IPCS, WHO, Geneva.
- JECFA, 2006c. Joint FAO/WHO Expert Committee on Food Additives. Sixty-seventh meeting. Rome, 20-29 June 2006, Summary and Conclusions. Issued 7 July 2006.
- Jonker D, 2000b. Sub-chronic (13-week) oral toxicity study in rats with micro-encapsulated furfural. Report V99.520. May, 1999. TNO, Zeist, The Netherlands.
- Kerckaert GA, Isfort RJ, Carr GJ, Aardema MJ and LeBoeuf RA, 1996. A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. *Mutat. Res.* 356, 64-84.
- Kim SB, Hayase F and Kato H, 1987b. Desmutagenic effect of alpha-dicarbonyl and alpha-hydroxycarbonyl compounds against mutagenic heterocyclic amines. *Mutat. Res.* 177, 9-15.
- Kitamura S, Koga H, Tatsumi K, Yoshimura H and Horiuchi T, 1978. Relationship between biological activities and enzymatic reduction of nitrofurans derivatives. *J. Pharm. Dyn.* 1, 15-21.
- Kowalski LA, Assi KP, Wee RK-H and Madden Z, 2001. *In vitro* prediction of carcinogenicity using a bovine papillomavirus DNA-carrying C3H/10T1/2 cell line (T1). II: Results from the testing of 100 chemicals. *Environ. Mol. Mutag.* 37(3), 231-240.
- Lake BG, 1998. An investigation of the effect of furfural on unscheduled DNA synthesis in cultured human liver slices. BIBRA International. Report no. 3033/2/4/98. February 6, 1998.
- Lee YC, Shlyankevich M, Jeong HK, Douglas JS and Surh YJ, 1995b. Bioactivation of 5-hydroxymethyl-2-furaldehyde to an electrophilic and mutagenic allylic sulfuric acid ester. *Biochem. Biophys. Res. Commun.* 209(3), 996-1002.
- Loquet C, Toussaint G and LeTalaer JY, 1981. Studies on the mutagenic constituents of apple brandy and various alcoholic beverages collected in western France, a high incidence area for oesophageal cancer. *Mutat. Res.* 88, 155-164.
- Majeska JB and McGregor DB, 1992. Effects of plate preparation on results in microbial mutation assays. *Environ. Molec. Mutagen.* 19(3), 244-252.
- Marnett LJ, Hurd HK, Hollstein MC, Levin DE, Esterbauer H and Ames BN, 1985a. Naturally-occurring carbonyl compounds are mutagens in *Salmonella* tester strain TA104. *Mutat. Res.* 148, 25-34.
- Matsui S, Yamamoto R and Yamada H, 1989. The *Bacillus Subtilis*/Microsome *rec*-assay for the detection of DNA damaging substances which may occur in chlorinated and ozonated waters. *Water Sci. Technol.* 21, 875-887.
- McGregor DB, McConville ML, Prentice RDM and Riach CG, 1981. Mutagenic activity of 123 compounds with known carcinogenic potential. Presented at 7th International Symposium on Chemical & Toxicological Aspects of Environmental Quality. September 7-10, London. Inveresk Research International Limited, Musselburgh.
- McGregor DB, Brown A, Cattanaach P, Edwards I, McBride D and Caspary WJ, 1988b. Responses of the L5178Y tk⁺/tk⁻ mouse lymphoma cell forward mutation assay II: 18 coded chemicals. *Environ. Mol. Mutag.* 11, 91-118.
- McMahon RE, Cline JC and Thompson CZ, 1979. Assay of 855 test chemicals in ten tester strains using a new modification of the ames test for bacterial mutagens. *Cancer Res.* 39, 682-693.
- Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B and Zeiger E, 1986. *Salmonella* mutagenicity tests II. Results from the testing of 270 chemicals. *Environ. Mol. Mutag.* 8(Suppl. 7), 1-119.
- Muñoz ER and Barnett MB, 1999. Meiotic nondisjunction induced by furfural in *Drosophila melanogaster* females. *Environ. Molec. Mutagen.* 34(1), 61-63.

- Nakamura SI, Oda Y, Shimada T, Oki I and Sugimoto K, 1987. SOS-inducing activity of chemical carcinogens and mutagens in *Salmonella typhimurium* TA1535/pSK1002: examination with 151 chemicals. *Mutat. Res.* 192, 239-246.
- Nishi Y, Miyakawa Y and Kato K, 1989. Chromosome aberrations induced by pyrolysates of carbohydrates in Chinese hamster V79 cells. *Mutat. Res.* 227, 117-123.
- NTP, 1990a. NTP technical report on the toxicology and carcinogenesis studies of furfural (CAS no. 98-01-1) in F344/N rats and B6C3F1 mice (gavage studies). March 1990. NTP-TR 382. NIH Publication no. 90-2837.
- NTP, 1999a. Toxicology and carcinogenesis studies of furfuryl alcohol (CAS no. 98-00-0) in F344/N rats and B6C3F1 mice (inhalation studies). February 1999. NTP-TR 482. NIH Publication no. 99-3972. NC.
- NTP, 2010c. National Toxicology Program. Toxicology and carcinogenesis studies of 5-(hydroxymethyl)-2-furfural (CAS No. 67-47-0) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program, Research Triangle, NC, USA. TR-554. NIH Publication No. 10-5895. [Online] http://ntp.niehs.nih.gov/ntp/htdocs/LT_rpts/TR554.pdf
- Omura H, Jahan N, Shinohara K and Murakami H, 1983. Formation of mutagens by the maillard reaction. In: Waller, G.R., Feather, M.S. (Eds.). *The Maillard Reaction in Foods and Nutrition*. ACS Symposium Series, 215. American Chemical Society, Washington D.C., pp. 537-563.
- Osawa T and Namiki M, 1982. Mutagen formation in the reaction of nitrite with the food components analogous to sorbic acid. *Agric. Biol. Chem.* 45, 2299-2304.
- Phillips BJ, Jackson LI, Tate B, Price RJ, Adams TB, Ford RA, Goodinan JI and Lake BJ, 1997. Furfural does not induce unscheduled DNA synthesis (UDS) in the *in vivo* rat hepatocyte DNA repair assay. Presented 1997 Society of Toxicol. Annu. Meeting, Cincinnati Ohio.
- Posternak NM, Linder A and Vodoz CA, 1969. Summaries of toxicological data. Toxicological tests on flavouring matters. *Food Cosmet. Toxicol.* 7, 405-407.
- Rodriguez-Arnaiz R, Morales PR, Moctezuma RV and Salas RMB, 1989. Evidence for the absence of mutagenic activity of furfuryl alcohol in tests of germ cells in *Drosophila melanogaster*. *Mutat. Res.* 223, 309-311.
- Rodriguez-Arnaiz R, Morales PR and Zimmering S, 1992. Evaluation in *Drosophila melanogaster* of the mutagenic potential of furfural in the mei-9(a) test for chromosome loss in germ-line cells. *Mutat. Res.* 280, 75-80.
- Sasaki Y and Endo R, 1978. Mutagenicity of aldehydes in *Salmonella*. *Mutat. Res.* 54, 251-252.
- SCF, 1999a. Opinion on a programme for the evaluation of flavouring substances (expressed on 2 December 1999). Scientific Committee on Food. SCF/CS/FLAV/TASK/11 Final 6/12/1999. Annex I the minutes of the 119th Plenary meeting. European Commission, Health & Consumer Protection Directorate-General.
- SCF, 2003a. Opinion of the Scientific Committee on Food on furfural and furfural diethylacetal (expressed on 2 December 2002). Scientific Committee on Food. SCF/CS/FLAV/FLAVOUR/11 ADD1 Final. 22 January, 2003. European Commission, Health & Consumer Protection Directorate-General.
- Severin I, Dumont C, Jondeau-Cabaton A, Graillot V and Chagnon M-C, 2010. Genotoxic activities of the food contaminant 5-hydroxymethylfurfural using different *in vitro* bioassays. *Toxicology Letters* 192, 189-194.
- Shane BS, Troxclair AM, McMillin DJ and Henry CB, 1988. Comparative mutagenicity of nine brands of coffee to *Salmonella typhimurium* TA100, TA102, and TA104. *Environ. Mol. Mutag.* 11, 195-206.
- Shinohara K, Kim E and Omura H, 1986. Furans as the mutagens formed by amino-carbonyl reactions. In: Fujimaki, M., Namiki, M., Kato, H., (Eds.). *Amino-Carbonyl Reactions in Food and Biological Systems*. Elsevier, New York.

- Sommer Y, Hollnagel H, Schneider H and Glatt HR, 2003. Metabolism of 5-hydroxymethyl-2-furfural (HMF) to the mutagen, 5-sulfoxymethyl-2-furfural (SMF) by individual human sulfotransferases. *Naunyn Schmiedebach's Arch. Pharmacol.* 367, Issue Supplement 1, R166.
- Soska J, Koukalova B and Ebringer L, 1981. Mutagenic activities of simple nitrofurans derivatives. I. Comparison of related compounds in the phage inductest, chloroplast-bleaching and bacterial repair and mutagenicity tests. *Mutat. Res.* 81(1), 21-26.
- Spalding JW, French JE, Stasiewicz S, Furedi-Machacek M, Conner F, Tice RR and Tennant RW, 2000. Responses of transgenic mouse lines p53(+/-) and Tg.AC to agents tested in conventional carcinogenicity bioassays. *Toxicol. Sci.* 53(2), 213-223.
- Stich HF, Rosin MP, San RHC, Wu CH and Powrie WD, 1981a. Intake, formation and release of mutagens by man. *Banbury Rep.* 7, 247-266.
- Stich HF, Rosin MP, Wu CH and Powrie WD, 1981b. Clastogenicity of furans found in food. *Cancer Lett.* 13, 89-95.
- Subramanyam S, Sailaja D and Rathnaprabha D, 1989. Genotoxic assay of two dietary furans by some *in vivo* cytogenetic parameters. *Environ. Mol. Mutag.* 14(15), 239.
- Sujatha PS and Subramanyam S, 1994. Clastogenicity of furfuryl alcohol in a mouse bone marrow system. *Med. Sci. Res.* 22(4), 281-284.
- Surh Y-J and Tannenbaum SR, 1994. Activation of the Maillard reaction product 5-(hydroxymethyl)furfural to strong mutagens via allylic sulfonation and chlorination. *Chem. Res. Toxicol.* 7, 313-318.
- Surh Y-J, Liem A, Miller JA and Tannenbaum SR, 1994. 5-Sulfoxymethylfurfural as a possible ultimate mutagenic and carcinogenic metabolite of the Maillard reaction product, 5-hydroxymethylfurfural. *Carcinogenesis* 15(10), 2375-2377.
- Woodruff RC, Mason JM, Valencia R and Zimmering S, 1985. Chemical mutagenesis testing in *Drosophila*. V. Results of 53 coded compounds tested for the National Toxicology Program. *Environ. Mutag.* 7, 677-702.
- Zang XM, Chan CC, Stamp D, Minkin S, Archer MC and Bruce WR, 1993. Initiation and promotion of colonic aberrant crypt foci in rats by 5-hydroxymethyl-2-furaldehyde in thermolyzed sucrose. *Carcinogenesis* 14, 773-775.
- Zdzienicka M, Tudek B, Zielenska M and Szymczyk T, 1978. Mutagenic activity of furfural in *Salmonella typhimurium* TA 100. *Mutat. Res.* 58, 205-209.

ABBREVIATIONS

| | |
|-------------------|---|
| ADI | Acceptable daily intake |
| BMDL _L | Benchmark Dose (Lower Confidence Limit). |
| BW | Body weight |
| CAS | Chemical Abstract Service |
| CEF | Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids |
| CHO | Chinese hamster ovary (cells) |
| CoE | Council of Europe |
| DNA | Deoxyribonucleic acid |
| EFSA | The European Food Safety Authority |
| ENU | Ethylnitrosourea |
| EPA | United States Environmental Protection Agency |
| EU | European Union |
| FAO | Food and Agriculture Organization of the United Nations |
| FEMA | Flavor and Extract Manufacturers Association |
| FGE | Flavouring Group Evaluation |
| FLAVIS (FL) | Flavour Information System (database) |
| GLP | Good laboratory practice |
| GSH | Glutathione |
| HMF | Hydroxymethylfurfuraldehyde |
| HPRT | Hypoxanthine phosphoribosyltransferase |
| ID | Identity |
| Ip | Intraperitoneal |
| IR | Infrared spectroscopy |
| JECFA | The Joint FAO/WHO Expert Committee on Food Additives |
| MSDI | Maximised Survey-derived Daily Intake |
| mTAMDI | Modified Theoretical Added Maximum Daily Intake |
| NCE | Normochromatic erythrocyte |

| | |
|-------|--|
| No | Number |
| NOAEL | No observed adverse effect level |
| NOEL | No observed effect level |
| NTP | National Toxicology Program |
| OECD | Organisation for Economic Co-operation and Development |
| PAPS | 3'-Phosphoadenosine-5'-phosphosulfate |
| PCE | Polychromatic erythrocyte |
| PFU | Plaque-forming units |
| SCE | Sister chromatic exchange |
| SCF | Scientific Committee on Food |
| UDS | Unsheduled DNA Synthesis |
| WHO | World Health Organisation |